RNA therapy for spinal cord injury
Lipid nanoparticles enhance the delivery and stability of circular mRNA encoding Sox2, Ascl1, and GDNF, addressing the challenges of spinal cord injury treatment by promoting neurogenesis and neuroprotection.
Patent Information
- Application Number
- PCT/US2026/026846
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Efficient delivery of Sox2, Ascl1, and GDNF for neurogenesis and neuroprotection in spinal cord injury is challenging due to the instability of linear mRNA and complexity of circular RNA synthesis.
Development of lipid nanoparticles containing specific lipid compounds and helper lipids to encapsulate circular mRNA encoding Sox2, Ascl1, and GDNF, enhancing stability and delivery efficiency.
The lipid nanoparticles effectively deliver therapeutic proteins, promoting neurogenesis and neuroprotection in spinal cord injury, with improved stability and expression of encoded factors.
Smart Images

Figure US2026026846_12112026_PF_FP_ABST
Abstract
Description
Docket No. 084284.00363PCT of 084284.00318 RNA THERAPY FOR SPINAL CORD INJURYCROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of priority to U. S. Provisional Patent Application No. 63 / 800,711 filed on May 6, 2025, the entire contents of which are incorporated herein by reference.FIELD
[0002] The present disclosure relates in general to formulations of lipid nanoparticles. The disclosure relates in particular to RNA therapy for treating spinal cord injury.BACKGROUND
[0003] Spinal cord injury (SCI) is a severe condition causing paralysis, sensory loss, and autonomic dysfunction. Despite advances in early surgical decompression, steroid treatment, and long-term rehabilitation, the prognosis remains poor, with fewer than 10 percent of patients achieving partial motor function recovery. The endogenous repair process involves diverse cell types, including neurons, astrocytes, microglia, Schwann cells, and oligodendrocyte precursor cells (OPCs), all contributing to neurogenesis, angiogenesis, axonal regeneration, and myelination. OPCs are particularly noteworthy because of their ability to proliferate and differentiate within the spinal cord, and their abundance in the central nervous system (CNS). They can be reprogrammed into neurons by several strategies, such as expression of SRY-box transcription factor 2 (Sox2) and achaete-scute family bHLH transcription factor 1 (Ascl1), achieving significant neurogenesis in vivo. In addition, neurotrophic factors like glial cell-derived neurotrophic factor (GDNF) are crucial for the survival and maturation of new neurons and facilitate regeneration after injury. Sox2, Ascii, and GDNF may be essential supplementary factors for promoting endogenous 1184884579.5Docket No. 084284.00363PCT of 084284.00318 neurogenesis and neuroprotection; however, efficiently delivering these three factors remains challenging.
[0004] RNA therapies such as messenger RNA (mRNA) have emerged as promising approaches for coding therapeutic proteins and gene editing. However, linear mRNA is prone to enzyme degradation and has limited stability, posing challenges for sustained expression. Circular RNA presents several advantages over linear mRNA, including enhanced stability against temperature fluctuations and enzymatic degradation.
[0005] By appropriately engineering components of circular RNA, such as internal ribosome entry site (IRES), untranslated region (UTR), and chemical modifications, circular RNA can achieve higher and longer expression than linear mRNA. Despite these advantages, the synthesis of circular RNA remains complex, typically requiring separate in vitro transcription (IVT) and circularization steps, followed by purification.
[0006] Given the foregoing, there is still an urgent need to develop innovative strategies to achieve synthesis of circular RNA that can be used to effectively treat spinal cord injury. This document describes compositions and methods that address some or all of the problems described above.SUMMARY
[0007] The present disclosure provides novel compounds and compositions involving the same.
[0008] In one aspect, the present disclosure relates to a lipid compound comprising a compound of Formula (I):2184884579.5Docket No. 084284.00363PCT of 084284.00318, andis a tail unit, wherein
[0009] Rl and R2 are independently C6-30 straight or branched saturated or unsaturated alkyl chain optionally inserted with one or more ester, carbonate (-O-(C=O)-O-), amide, nitrogen (-N-) or oxygen (-O-), and R1 and R2 are optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, hydroxyl,R3 is C, N, or O; R4 and R5 are independently void, hydrogen, (-OH), a straight or branched Ci-20 alkyl chain, or a 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring; or R4 and R5 form a 3-6 membered homocyclic or heterocyclic ring with R3, wherein when R4 and R5 form a 3-6 membered homocyclic or heterocyclic ring with R3, the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and is optionally substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, Ci-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, and (-OH), wherein when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo- 3184884579.5Docket No. 084284.00363PCT of 084284.00318 Ci -20 alkyl, hydroxy-Ci-20 alkyl, halogen, and (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein when R4 or R5 is a 3-6 membered homocyclic or heterocyclic ring, any atom on the ring is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, and (-OH), RIO and Rll are independently a straight or branched C1-20 alkyl chain, R6 is void, a bond, or a C1-20 straight or branched alkyl chain, wherein R6 is optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), R9 is void, a bond, carbon, or nitrogen, and R7 and R8 are independently void, hydrogen, or a straight or branched C1-20 alkyl chain, or R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with R9, wherein when R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with R9, the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), wherein when R7 or R8 is a straight or branched C1-20 alkyl chain, R7 or R8 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and is optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)), and R12 and R13 are independently a straight or branched C1-20 alkyl chain, wherein R12 or R13 are optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl.
[0010] In some embodiments, the head group comprises Formula (IA):4184884579.5Docket No. 084284.00363PCT of 084284.00318(IA), wherein
[0011] R6, R7, R8, and R9 are void, and R4 and R5 are independently void, hydrogen, (- OH), a straight or branched C1-20 alkyl chain, 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring, or R4 and R5 form 3-6 membered homocyclic or heterocyclic ring with R3, wherein when R4 and R5 form 3-6 membered homocyclic or heterocyclic ring with R3, the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), wherein when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), and wherein when R4 or R5 is saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring, any atom on the ring may optionally be substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and R10 and Rll are independently a straight or branched C1-20 alkyl chain.
[0012] In some embodiments, the head group comprises Formula (IB):5184884579.5Docket No. 084284.00363PCT of 084284.00318(IB), wherein
[0013] R4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring, wherein when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein when R4 or R5 is 3-6 membered homocyclic or heterocyclic ring, any atom on the ring may optionally be substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-C 1-20 alkyl, halogen, or (-OH), R6 is C1-20 straight or branched alkyl chain, wherein R6 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-C 1-20 alkyl, halogen, or (-OH), R7 and R8 are independently void, hydrogen, a straight or branched C1-20 alkyl chain, or R7 and R8 form 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-C 1-20 alkyl, halogen, or (-OH), wherein when R7 and R8 form 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen,6184884579.5Docket No. 084284.00363PCT of 084284.00318 or (-OH), wherein when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 are optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and R7 and R8 are optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)), and R12 and R13 are independently a straight or branched C1-20 alkyl chain, wherein R12 or R13 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl.
[0014] In some embodiments, the head group comprises Formula (IC):(IC), wherein
[0015] R6 is C1-20 straight or branched alkyl chain, wherein R6 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), R7 and R8 are independently void, hydrogen, a straight or branched C1-20 alkyl chain, or R7 and R8 form 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), wherein when R7 and R8 form 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen,7184884579.5Docket No. 084284.00363PCT of 084284.00318 or (-OH), wherein when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 are optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and R7 and R8 are optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)), and R12 and R13 are independently a straight or branched Cl-20 alkyl chain.
[0016] In some embodiments, the head group comprises Formula (ID):(ID), wherein
[0017] In some embodiments, R4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, or a 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring, wherein when R4 or R5 is a straight or branched Ci -20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-C 1-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein when R4 or R5 is a 3-6 membered homocyclic or heterocyclic ring, any atom on the 3-6 membered homocyclic or heterocyclic ring may optionally be substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), R10 and Rll are independently a straight or branched C1-20 alkyl chain, R6 is a bond or a C1-20 straight or branched alkyl chain, wherein when R6 is a C1-20 straight or branched alkyl chain, it is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl,8184884579.5Docket No. 084284.00363PCT of 084284.00318 halo-Ci -20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), R7 and R8 are independently void, hydrogen, or a straight or branched C1-20 alkyl chain, or R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), wherein when R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), wherein when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 are optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and R7 and R8 are optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)), R12 and R13 are independently a straight or branched C1-20 alkyl chain, wherein R12 or R13 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl.
[0018] In some embodiments, R1 and R2 are independently selected from the group consisting of: -C2-20 straight or branched alkyl optionally inserted with one or more oxygen (-O-);-C2-20 alkenyl optionally substituted with C1-20 alkyl; -C2-20 alkylene-((CH2)nO)m-Ci-2o alkyl; wherein n and m are independently selected from 1-5; and -C2-10 alkylene-ester-Ci-20 linear or branched alkyl optionally substituted with C1-20 alkyl.9184884579.5Docket No. 084284.00363PCT of 084284.00318
[0019] In some embodiments, R1 and R2 are independently selected from the group consisting of:184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318
[0020] In some embodiments, the head group is selected from the group consisting of:184884579.5Docket No. 084284.00363PCT of 084284.00318
[0021] In some embodiments, the compound of Formula (I) is selected from:14184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.0031816184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.0031821184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318
[0022] In another aspect, the present disclosure relates to a lipid compound comprising two or more compounds of Formula (I):
[0023] wherein R9 is N, wherein k is between 0-20, wherein when k is 0, a compound of Formula (la) is bonded to a compound of Formula (Ic) by covalent bonding between R9 of the compound of Formula (la) and R9 of the compound of Formula (Ic) through a straight or branched Ci-20 alkyl chain, optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and wherein when k is greater than 0, the compound of Formula (la) is bonded to a compound of (Ib)k by covalent bonding between R9 of the compound of Formula (la) and R9 of the compound of Formula (Ib)k through a straight or branched C1-20 alkyl chain, optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-2023184884579.5Docket No. 084284.00363PCT of 084284.00318 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and the compound of (Ib)k is bonded to the compound of Formula (Ic) by covalent bonding between R9 of the compound of Formula (Ib)k and R9 of the compound of Formula (Ic) through a straight or branched C1-20 alkyl chain, optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0024] In another aspect, the present disclosure relates to a lipid nanoparticle composition comprising a lipid compound of any one of claims 1-9 and a helper lipid.
[0025] In some embodiments, the helper lipid comprises a phospholipid, a structural lipid, a pegylated lipid, or a combination thereof.
[0026] In some embodiments, the phospholipid is selected from the group consisting of Dilauroyl lecithin (DLPC), Dimyristoyl phosphatidylcholine (DMPC), Dioleoyl lecithin (DOPC), Dipalmitoyl phosphatidylcholine (DPPC), Distearoyl phosphatidylcholine (DSPC), Dioleoyl phosphatidylcholine (DUPC), Palmitoyl oleoyl phosphatidylcholine (POPC), 1,2-Di-O-octadecyl-sn-glycero-3 -phosphocholine, l-Oleoyl-2-cholesteryldimethylsuccinoyl-sn-glycero-3-phosphocholine, 1 -Hexadecyl-sn-glycero-3 -phosphocholine, 1,2-Divinyl-sn-glycero-3 -phosphocholine, 1,2-Diarylacyl-sn-glycero-3 -phosphocholine, 1,2-Dioleoyl-sn-glycero-3 -phosphorylethanolamine (DOPE), l,2-Di-phytanoyl-sn-glycero-3 -phosphoethanolamine, 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine, l,2-Diethenol-sn-glycero-3-phosphoethanolamine, 1,2-Divinyl-sn-glycero-3 -phosphoethanolamine, 1,2-Diaryl-sn-glycero-3 -phosphoethanolamine, 1,2-Dithiohexaenoate-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphate-(l -glycerol) sodium salt (DOPG), and combinations thereof.24184884579.5Docket No. 084284.00363PCT of 084284.00318
[0027] In some embodiments, the structural lipid is selected from the group consisting of cholesterol, coprosterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof.
[0028] In some embodiments, the pegylated-lipid is selected from the group consisting of 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (DMG-PEG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), PEG-disteryl glycerol (DSG-PEG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (DAGPEG), PEG-dipalmitoyl phosphatidylethanolamine (DPPE-PEG), or PEG- 1,2-dimyristyloxypropyl-3-amine (DMA-c-PEG), and combinations thereof.
[0029] In some embodiments, the phospholipid is DOPE, the structural lipid is cholesterol, and the pegylated-lipid is DMG-PEG.
[0030] In some embodiments, the lipid nanoparticle further comprises an mRNA encapsulated in the lipid nanoparticle composition. In some embodiments, the mRNA encodes a neurotrophic factor. In some embodiments, the mRNA encodes SRY-box transcription factor 2 (Sox2), achaete-scute family bHLH transcription factor 1 (Ascl1), glial cell line-derived neurotrophic factor (GDNF), Insulin-like Growth Factor 1 (IGF-1), Ciliary Neurotrophic Factor (CNTF), Fibroblast Growth Factor 2 (FGF2), Epidermal Growth Factor (EGF), Brain-Derived Neurotrophic Factor (BDNF), or a combination thereof.
[0031] In another aspect, the present disclosure relates to a method of intracellular delivery of a therapeutic agent, comprising contacting a cell or administering to a subject a lipid nanoparticle composition of the present disclosure.25184884579.5Docket No. 084284.00363PCT of 084284.00318
[0032] In another aspect, the present disclosure relates to a method for treating spinal cord injury comprising administering to a subject an effective amount of a lipid nanoparticle composition of the present disclosure.
[0033] In some embodiments, the lipid nanoparticle composition comprises a circular mRNA. In some embodiments, the circular mRNA encodes SRY-box transcription factor 2 (Sox2), achaete-scute family bHLH transcription factor 1 (Ascl1), glial cell line-derived neurotrophic factor (GDNF), Insulin-like Growth Factor 1 (IGF-1), Ciliary Neurotrophic Factor (CNTF), Fibroblast Growth Factor 2 (FGF2), Epidermal Growth Factor (EGF), Brain-Derived Neurotrophic Factor (BDNF), or a combination thereof.
[0034] In some embodiments, the administering comprises intravenously injecting the lipid nanoparticle composition, locally delivering the lipid nanoparticle composition, or a combination thereof. In some embodiments, the spinal cord injury is selected from the group consisting of traumatic spinal cord injury, non-traumatic spinal cord injury, contusion injury, compression injury, laceration, transection, ischemic injury, inflammatory demyelination, and iatrogenic spinal cord injury, including injuries resulting from tumor resection, vascular malformations, surgical complications, or a combination thereof.
[0035] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.BRIEF DESCRIPTION OF THE DRAWINGS
[0036] FIG. 1 is a graph illustrating the LNP particle size and zeta potential of aminophosphate, aminophosphonate, or aminophosphoramidate-derived LNPs of the present disclosure.
[0037] FIG. 2 is a graph illustrating the mRNA luminescence intensity in major organs.26184884579.5Docket No. 084284.00363PCT of 084284.00318
[0038] FIG. 3 is a graph illustrating the luminescence intensity of the spinal cord lesion locally or intravenously delivered by AP60 and MC3 LNPs.
[0039] FIG. 4 is a graph illustrating luminescence intensity of linear and circular luciferase RNA expression in mice with spinal cord injury.
[0040] FIG. 5 is a graph illustrating the reprogramming of OPCs into neurons via CROSS.
[0041] FIG. 6 is a graph illustrating another embodiment of the reprogramming of OPCs into neurons via CROSS.DETAILED DESCRIPTION
[0042] The following discussion omits or only briefly describes conventional features of the disclosed technology that are apparent to those skilled in the art. Reference to various embodiments does not limit the scope of the claims attached hereto. Additionally, any examples set forth in this specification are intended to be non-limiting and merely set forth some of the many possible embodiments for the appended claims. Further, particular features described herein can be used in combination with other described features in each of the various possible combinations and permutations. A person of ordinary skill in the art would know how to make and use the disclosed technology, in combination with routine experiments, to achieve other outcomes not specifically disclosed in the examples or the embodiments.
[0043] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present disclosure, the preferred materials and methods are described herein. In describing and claiming the present disclosure, the following terminology27184884579.5Docket No. 084284.00363PCT of 084284.00318 will be used. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0044] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. Thus, recitation of “a cell”, for example, includes a plurality of cells of the same type. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and / or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”
[0045] “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of + / - 20%, + / - 10%, + / - 5%, + / -1%, or + / - 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude within 5-fold, and also within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.
[0046] As used herein, the terms “agent” or “therapeutic agent” are meant to encompass any molecule, chemical entity, composition, drug, therapeutic agent, chemotherapeutic agent, or biological agent capable of preventing, ameliorating, or treating a disease or other medical condition. The term includes small molecule compounds, antisense reagents, mRNA, siRNA reagents, antibodies, antibody fragments bearing epitope recognition sites, such as Fab, Fab’, F(ab’)2 fragments, Fv fragments, single chain antibodies, antibody mimetics (such as DARPins, affibody molecules, affilins, affitins, anticalins, avimers, fynomers, Kunitz domain peptides and monobodies), peptoids, aptamers, hormones, oligonucleotides, enzymes, peptides, organic or28184884579.5Docket No. 084284.00363PCT of 084284.00318 inorganic molecules, natural or synthetic compounds and the like. An agent can be assayed in accordance with the methods of the disclosure at any stage during clinical trials, during pre-trial testing, or following FDA-approval.
[0047] As used herein, the terms “comprising,” “comprise” or “comprised,” and variations thereof, in reference to defined or described elements of an item, composition, apparatus, method, process, system, etc. are meant to be inclusive or open-ended, permitting additional elements, thereby indicating that the defined or described item, composition, apparatus, method, process, system, etc. include those specified elements— or, as appropriate, equivalents thereof— and that other elements can be included and still fall within the scope / definition of the defined item, composition, apparatus, method, process, system, etc.
[0048] An “effective amount” as used herein, means an amount that provides a therapeutic or prophylactic benefit.
[0049] The term “encapsulation efficiency” as used herein refers to the percentage of nucleic acid in the lipid nanoparticles that is not degraded after exposure to serum or a nuclease assay that would significantly degrade free nucleic acids. As used herein, “encapsulation” may refer to complete, substantial, or partial enclosure, confinement, surrounding, or encasement.
[0050] The term “fully encapsulated” as used herein indicates that the mRNA in the nanoparticles is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade free nucleic acids. In a fully encapsulated system, preferably less than 25% of particle nucleic acid is degraded in a treatment that would normally degrade 100% of free nucleic acid, more preferably less than 10%, and most preferably less than 5% of the particle nucleic acid is degraded. Fully encapsulated also indicates that the particles are serum stable, that is, that they do not rapidly decompose into their component parts upon in vivo administration.29184884579.5Docket No. 084284.00363PCT of 084284.00318
[0051] As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).
[0052] As used herein, the term “in vivo” refers to events that occur within an organism (e g., animal, plant, or microbe or cell or tissue thereof).
[0053] The term “lipid nanoparticle” refers to a nanoparticle that includes lipids and that is stable and dispersible in aqueous media. As used herein, the term “nanoparticle” refers to a particle having one or a plurality of components, the particle having any one structural feature on a scale of less than about 1000 nm that exhibits novel properties as compared to a bulk sample of the same material or component materials. Routinely, nanoparticles have any one structural feature on a scale of less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm. In exemplary embodiments, a nanoparticle is a particle having one or more dimensions of the order of about 10 nm to about 500 nm. In other exemplary embodiments, a nanoparticle is a particle having one or more dimensions of the order of about 10 nm to about 1000 nm. A spherical nanoparticle would have a diameter, for example, of between 10 nm to about 100 nm or 10 nm to about 1000 nm.
[0054] A nanoparticle most often behaves as a unit in terms of its physical or biophysical properties, e.g., transport. It is noted that novel properties that differentiate nanoparticles from the corresponding bulk material typically develop at a size scale of under 1000 nm, or at a size of under 500 nm, but nanoparticles can be of a larger size, for example, for particles that are oblong, tubular, and the like. The size at which materials display different properties as compared to the bulk material is material-dependent and can be seen for many materials much larger in size than 100 nm and even for some materials larger in size than 1000 nm. Nanoparticles can be employed30184884579.5Docket No. 084284.00363PCT of 084284.00318 in a variety of drug delivery technologies (e.g., mRNA delivery technologies) and can be employed for various purposes including, but not limited to, controlled drug delivery, protection of the drugs from degradation, and protection of the body from the toxic effects of the drugs.
[0055] As used herein, the term “carbocycle” or “carbocyclic group” means an optionally substituted mono- or multi-cyclic system including one or more rings of carbon atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty membered rings. The notation “C3-6 carbocycle” means a carbocycle including a single ring having 3-6 carbon atoms. Carbocycles may include one or more carbon-carbon double or triple bonds and may be non-aromatic or aromatic (e.g., cycloalkyl or aryl groups). Examples of carbocycles include cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and 1,2-dihydronaphthyl groups. The term “cycloalkyl” as used herein means a non-aromatic carbocycle and may or may not include any double or triple bond. Unless otherwise specified, carbocycles described herein refer to both unsubstituted and substituted carbocycle groups, i.e., optionally substituted carbocycles.
[0056] As used herein, the term “heterocycle” or “heterocyclic group” means an optionally substituted mono- or multi-cyclic system including one or more rings, where at least one ring includes at least one heteroatom. Heteroatoms may be, for example, nitrogen, oxygen, or sulfur atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen membered rings. Heterocycles may include one or more double or triple bonds and may be non-aromatic or aromatic (e.g., heterocycloalkyl or heteroaryl groups). Examples of heterocycles include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and31184884579.5Docket No. 084284.00363PCT of 084284.00318 isoquinolyl groups. The term “heterocycloalkyl” as used herein means a non-aromatic heterocycle and may or may not include any double or triple bond. Unless otherwise specified, heterocycles described herein refer to both unsubstituted and substituted heterocycle groups, i.e., optionally substituted heterocycles.
[0057] As used herein, the term “alkyl” refers to a group containing one or more carbon atoms (for example, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more carbon atoms), which may be optionally substituted. For instance, the term “Ci-36 alkyl” refers to an optionally substituted linear or branched saturated or unsaturated hydrocarbon containing from 1 to 36 carbon atoms, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36. Unless otherwise explicitly indicated, unsaturated alkyl groups may contain one or more double or triple bonds along the carbon chain. Unless otherwise explicitly indicated, alkyl groups described herein refer to both unsubstituted and substituted alkyl groups. As used herein, an alkyl group may be terminated with a different functional group such as primary amino (-NH2), secondary amino (-NR1H), or tertiary amino (-NR1R2). For instance, a C5 alkyl group terminated with a primary amino (-NH2) may have a structure (-(CH2)5-NH2).
[0058] Additionally, the terms “halo-alkyl,” “hydroxy-alkyl,” and the like refer to an alkyl chain terminated with a halo-group (i.e., “halogen”) or a hydroxyl (-OH) group. In the case of halo-alkyl, one, two or three halogens (i.e., F, Cl, Br, I) may be bonded to the terminal carbon of the alkyl chain. As used herein, an alkyl group may be connected to other carbon chain groups containing heteroatoms (e.g., O, N, or S). For instance, C5 alkoxyl-Cs alkyl means an alkoxy group containing a heteroatom (oxygen) is bonded to an alkyl chain having 5 carbons in length.32184884579.5Docket No. 084284.00363PCT of 084284.00318
[0059] As used herein, the term “alkylene” refers to a straight, branched chain, or cyclic structure of chain divalent, trivalent, or tetravalent hydrocarbon radical having from 1 to 36 carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkyl sulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such an “alkylene” group may contain one or more O, S, S(O), or S(O)2 atoms.
[0060] Examples of “alkylene” as used herein include, but are not limited to, methylene, ethylene, propylene, ethan- 1,1 -diyl, ethan-l,2-diyl, propan- 1,1 -diyl, propan- 1,3 -diyl, propan- 1,2-diyl, butan-l,4-diyl, butan- 1,3 -diyl, butan-l,2-diyl, 2-methyl-propan-l,3-diyl, and the like. Unless otherwise explicitly indicated, alkylene groups described herein refer to both unsubstituted and substituted alkylene groups.
[0061] As used herein, “cycloalkyl” refers to an alicyclic hydrocarbon group optionally possessing one or more degrees of unsaturation, having from three to twelve carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. “Cycloalkyl” includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and the like. Unless33184884579.5Docket No. 084284.00363PCT of 084284.00318 otherwise explicitly indicated, cycloalkyl groups described herein refer to both unsubstituted and substituted cycloalkyl groups.
[0062] As used herein, “halide,” “halo,” or “halogen” refers to a chloro, bromo, fluoro, or iodo atom radical. Similarly, as used herein, “haloalkyl” means a hydrocarbon substituent, which is a linear or branched, alkyl, alkenyl, or alkynyl substituted with one or more chloro, bromo, fluoro, and / or iodo atom(s). Similarly, as used herein, “halo-Cn-malkyl” or “Cn-m haloalkyl” refers to an alkyl group having from one halogen atom to 2s+ 1 halogen atoms which may be the same or different, where “s” is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the alkyl group has 1, 2, 3, 4, or 5 carbon atoms.
[0063] As disclosed throughout this document, all stereoisomers of the compounds are encompassed by the foregoing formulas. When no particular stereoisomer or stereochemistry is indicated, it is understood to mean all possible stereoisomers that could be produced from a reaction are present. A person of ordinary skill in the art will recognize that the reactions can be optimized to give one isomer preferentially, or new schemes may be devised to produce a single isomer.
[0064] In one aspect, the lipid compounds are described herein having Formula (I):34184884579.5Docket No. 084284.00363PCT of 084284.00318
[0065] As used herein, a dashed line between atoms / variables represents a bond that may or may not be present depending on other variables, including but not limited to chemical environment, valence state, tautomeric form, resonance structure, protonation state, coordination state, or alternative embodiments of the compound. Accordingly, the dashed bond denotes a conditional or optional bonding interaction and is not intended to require the existence of the bond in all embodiments unless expressly stated otherwise.
[0066] In some embodiments, R1 and R2 may independently be C6-30 straight or branched saturated or unsaturated alkyl chain optionally inserted with one or more ester, carbonate (-O-(C=O)-O-), amide, nitrogen (-N-) or oxygen (-O-), and may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-C 1-20 alkyl, halo-Ci-20 alkyl, hydroxy-C 1-20 alkyl, halogen, (-OH). In some embodiments, R3 may be C, N, or O, R4 and R5 may independently be void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring. In some embodiments, R4 and R5 may form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with R3.
[0067] In some embodiments, when R4 and R5 form 3-6 membered homocyclic or heterocyclic ring with R3, 3-6 membered homocyclic or heterocyclic ring may comprise O, N, or C in the ring, and may optionally be substituted at any ring with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)). In some embodiments, when R4 or R5 is saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring, any atom on the ring may optionally35184884579.5Docket No. 084284.00363PCT of 084284.00318 be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-C1-20 alkyl, halogen, or (-OH). In some embodiments, RIO and Rll may independently be a straight or branched C1-20 alkyl chain.
[0068] In some embodiments, R6 may be void, bond, or C1-20 straight or branched alkyl chain, wherein R6 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, R9 may be void, bond, carbon, or nitrogen. In some embodiments, R7 and R8 may independently be void, hydrogen, or a straight or branched C1-20 alkyl chain. In some embodiments, R7 and R8 may form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with R9.
[0069] In some embodiments, when R7 and R8 form 3-6 membered homocyclic or heterocyclic ring with R9, the 3-6 membered homocyclic or heterocyclic ring may comprise O, N, or C in the ring, and may optionally be substituted at any ring position with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, when R7 or R8 is a straight or branched C1-20 alkyl chain, R7 or R8 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-C1-20 alkyl, halogen, or (-OH) and is optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)). In some embodiments, R12 and R13 may independently be a straight or branched C1-20 alkyl chain and may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0070] As disclosed herein, all subsets of the head group of Formula (I), including Formulas (IA), (IB), (IBa), (IC), (ICa), (IDa), (IDb), and (IDc), are encompassed by the variables (e g., Rl, R2, R3, R4, R5, R6, R7, R8, R9, R10, Rll, R12) as defined in Formula (I) discussed36184884579.5Docket No. 084284.00363PCT of 084284.00318 above, as well as by any additional variables disclosed below with respect to each subset of the head group of Formula (I).
[0071] In certain embodiments, a subset of head groups of compounds of Formula (I) includes those of Formula (IA):
[0072] wherein R4 and R5 are independently void, hydrogen, (-OH), a straight or branched Ci-20 alkyl chain, or a saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring. In some embodiments, R4 and R5 may form a saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with R3.
[0073] In some embodiments, R4 and R5 may form 3-6 membered homocyclic or heterocyclic ring with R3, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-C1-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)).
[0074] In some embodiments, R4 or R5 may be saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring, and any atom on the ring may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or184884579.5Docket No. 084284.00363PCT of 084284.00318 (-0H). In some embodiments, RIO and Rll may independently be a straight or branched C1-20 alkyl chain.
[0075] In certain embodiments, a subset of head groups of compounds of Formula (I) includes those of Formula (IB):(IB),
[0076] wherein R4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring. In some embodiments, when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)). In some embodiments, R4 or R5 may be a saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring, and any atom on the ring may optionally be substituted with one or more of Ci-20 alkyl, Ci -20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, R6 may be a C1-20 straight or branched alkyl chain, wherein R6 is optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0077] In some embodiments, R7 and R8 may independently be void, hydrogen, or a straight or branched C1-20 alkyl chain. In some embodiments, R7 and R8 may form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring. In some embodiments, when R7184884579.5Docket No. 084284.00363PCT of 084284.00318 and R8 form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0078] In some embodiments, R7 or R8 may be a straight or branched C1-20 alkyl chain, and may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, R7 and R8 may optionally be terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)). In some embodiments, R12 and R13 may independently be a straight or branched C1-20 alkyl chain, and R12 or R13 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0079] In certain embodiments, a subset of head groups of compounds of Formula (I) and Formula (IB) includes those of Formula (IBa):
[0080] wherein R4 is hydrogen or a straight or branched C1-20 alkyl chain. In some embodiments, when R4 is a straight or branched C1-20 alkyl chain, R4 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)). In some embodiments, R6 may be a C1-20 straight or39184884579.5Docket No. 084284.00363PCT of 084284.00318 branched alkyl chain, wherein R6 is optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0081] In some embodiments, R7 and R8 may independently be hydrogen, or a straight or branched C1-20 alkyl chain. In some embodiments, when R7 or R8 is a straight or branched C1-20 alkyl chain, R7 or R8 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-C1-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0082] In certain embodiments, a subset of head groups of compounds of Formula (I) includes those of Formula (IC):
[0083] wherein R6 is C1-20 straight or branched alkyl chain, and may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, R7 and R8 may independently be void, hydrogen, or a straight or branched C1-20 alkyl chain. In some embodiments, R7 and R8 may form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring. In some embodiments, when R7 and R8 form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0084] In some embodiments, when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl,40184884579.5Docket No. 084284.00363PCT of 084284.00318 halo-Ci -20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). Tn some embodiments, R7 and R8 may optionally be terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)). In some embodiments, R12 and R13 are independently a straight or branched C1-20 alkyl chain.
[0085] In certain embodiments, a subset of head groups of compounds of Formula (I) and Formula (IC) includes those of Formula (ICa):
[0086] wherein R6 is C1-3 straight alkyl. In some embodiments, R7 and R8 may independently be hydrogen or a straight or branched C1-20 alkyl chain. In some embodiments, R7 and R8 are independently selected from the group consisting of hydrogen and C1-6 alkyl; when R7 or R8 is C1-6 alkyl, R7 and R8 are optionally substituted with OH, NHC1-6 alkyl, or N(CI-6 alkyl).
[0087] In certain embodiments, a subset of head groups of compounds of Formula (I) includes those of Formula (ID):
[0088] wherein R4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring. In some embodiments, when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and may optionally 41184884579.5Docket No. 084284.00363PCT of 084284.00318 be terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)).In some embodiments, R10 and Rll are independently a straight or branched C1-20 alkyl chain.
[0089] In some embodiments, when R4 or R5 is saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring, any atom on the ring may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). In some embodiments, R6 is a bond or C1-20 straight or branched alkyl chain. In some embodiments, when R6 is Ci -20 straight or branched alkyl chain, R6 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0090] In some embodiments, R7 and R8 may independently be void, hydrogen, a straight or branched C1-20 alkyl chain. In some embodiments, R7 and R8 may form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring. In some embodiments, when R7 and R8 form saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0091] In some embodiments, when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH) and may optionally be terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)). In some embodiments, R12 and R13 may independently be a straight or branched C1-20 alkyl chain wherein R12 or R13 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-C1-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).42184884579.5Docket No. 084284.00363PCT of 084284.00318
[0092] In certain embodiments, a subset of head groups of compounds of Formula (I) and Formula (ID) includes those of Formula (IDa):
[0093] In some embodiments, R4 is hydrogen or C1-3 alkyl, R6 is C1-3 alkyl, R7 and R8 are independently selected from the group consisting of hydrogen and Ci-6 alkyl, wherein R7 and R8 are optionally substituted with OH, NHCI-6 alkyl, or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein RIO and Rll are independently C1-3 alkyl. In some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring.
[0094] In certain embodiments, a subset of head groups of compounds of Formula (I) and Formula (ID) includes those of Formula (IDb):
[0095] In some embodiments, R4 is C1-3 alkyl, R6 is C1-3 alkyl, R7 and R8 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein R7 and R8 are optionally substituted with OH, NHC1-6 alkyl, or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein R10 and Rll are independently C1-3 alkyl. In some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring. In some embodiments, R4 is a 5-membered saturated or184884579.5Docket No. 084284.00363PCT of 084284.00318 unsaturated heterocyclic ring, wherein the ring includes an O, optionally substituted with C1-3 alkyl or OH.
[0096] In certain embodiments, a subset of head groups of compounds of Formula (I) and Formula (ID) includes those of Formula (IDc):(IDc).
[0097] In some embodiments, R4 and R5 are independently H or C1-3 alkyl, R6 is C1-4alkyl optionally substituted with OH (e.g.R7 and R8 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein R7 and R8 are optionally substituted with OH, NHC1-6 alkyl, or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein RIO and Rll are independently C1-3 alkyl. In some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring.
[0098] In some embodiments, R4 and R5 are independently H, R6 is C1-4 alkyl optionallysubstituted with OH (e.g.R7 and R8 are independently selected from the group consisting of C1-6 alkyl, wherein R7 and R8 are optionally substituted with NHC1-6 alkyl or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein R10 and Rll are independently C1-3 alkyl. In some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring.
[0099] In some embodiments, the head group according to Formulas (I), (IA), (IB), (IC), or (ID) may be selected from the following:184884579.5Docket No. 084284.00363PCT of 084284.00318
[0100] In some embodiments, R1 and R2 in Formula (I) may independently comprise -C2- 20 straight or branched alkyl optionally inserted with one or more oxygen (-O-), -C2-20 alkenyl optionally substituted with C1-20 alkyl, -C2-20 alkyl ene-((CH2)nO)m-C 1-20 alkyl; wherein n and m are 45184884579.5Docket No. 084284.00363PCT of 084284.00318 independently selected from 1-5, and -C2-10 alkyl ene-ester-Ci-20 linear or branched alkyl optionally substituted with C1-20 alkyl. In some embodiments, R1 and R2 may independently be selected from the following:46184884579.5Docket No. 084284.00363PCT of 084284.0031847184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318
[0101] In some embodiments, the lipid compounds described herein having Formula (I) may comprise any combination of a head group according to Formulas (1A), (IB), (IBa), (1C), (ICa), (IDa), (IDb), and (IDc) and a tail group.
[0102] In certain embodiments, a subset of Formula (I) includes those of Formula (II):
[0103] wherein R1 and R2 are independently -C2-20 straight or branched alkyl optionally inserted with one or more oxygen (-O-), -C2-20 alkenyl optionally substituted with C1-20 alkyl, -C2-20 alkylene-((CH2)nO)m-Ci-2o alkyl; wherein n and m are independently selected from 1-5, and -C2-49184884579.5Docket No. 084284.00363PCT of 084284.00318 io alkylene-ester-Ci-20 linear or branched alkyl optionally substituted with C1-20 alkyl, R4 is hydrogen or a straight or branched C1-20 alkyl chain. In some embodiments, when R4 is a straight or branched C1-20 alkyl chain, R4 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)). In some embodiments, R6 may be a C1-20 straight or branched alkyl chain, wherein R6 is optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0104] In some embodiments, R7 and R8 may independently be hydrogen, or a straight or branched C1-20 alkyl chain. In some embodiments, when R7 or R8 is a straight or branched C1-20 alkyl chain, R7 or R8 may optionally be substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-C1-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0105] In certain embodiments, a subset of Formula (I) includes those of Formula (III):
[0106] wherein R1 and R2 are independently -C2-20 straight or branched alkyl optionally inserted with one or more oxygen (-O-), -C2-20 alkenyl optionally substituted with C1-20 alkyl, -C2-20 alkylene-((CH2)nO)m-Ci-2o alkyl; wherein n and m are independently selected from 1-5, and -C2-10 alkylene-ester-Ci-20 linear or branched alkyl optionally substituted with C1-20 alkyl, R6 is C1-3 straight alkyl. In some embodiments, R7 and R8 may independently be hydrogen or a straight or branched C1-20 alkyl chain. In some embodiments, R7 and R8 are independently selected from the184884579.5Docket No. 084284.00363PCT of 084284.00318 group consisting of hydrogen and Ci-6 alkyl; when R7 or R8 is Ci-6 alkyl, R7 and R8 are optionally substituted with OH, NHCi 6 alkyl, or N(CI-6 alkyl)2.
[0107] In certain embodiments, a subset of Formula (I) includes those of Formula (IV):
[0108] In some embodiments, R1 and R2 are independently -C2-20 straight or branched alkyl optionally inserted with one or more oxygen (-O-), -C2-20 alkenyl optionally substituted with C1-20 alkyl, -C2-20 alkylene-((CH2)nO)m-Ci-2o alkyl; wherein n and m are independently selected from 1-5, and -C2-10 alkylene-ester-Ci-20 linear or branched alkyl optionally substituted with C1-20 alkyl, R4 is hydrogen or C1-3 alkyl, R6 is C1-3 alkyl, R7 and R8 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein R7 and R8 are optionally substituted with OH, NHCI-6 alkyl, or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein R10 and Rll are independently C1-3 alkyl. In some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring.
[0109] In certain embodiments, a subset of Formula (I) includes those of Formula (V):
[0110] In some embodiments, R1 and R2 are independently -C2-20 straight or branched alkyl optionally inserted with one or more oxygen (-O-), -C2-20 alkenyl optionally substituted with C1-20 alkyl, -C2-20 alkylene-((CH2)nO)m-Ci-2o alkyl; wherein n and m are independently selected 51184884579.5Docket No. 084284.00363PCT of 084284.00318 from 1-5, and -C2-10 alkylene-ester-Ci-20 linear or branched alkyl optionally substituted with C1-20 alkyl, R4 is C1-3 alkyl, R6 is C1-3 alkyl, R7 and R8 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein R7 and R8 are optionally substituted with OH, NHC1-6 alkyl, or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R1O)(R11)), wherein RIO and Rll are independently Ci-3 alkyl. In some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring. In some embodiments, R4 is a 5-membered saturated or unsaturated heterocyclic ring, wherein the ring includes an O, optionally substituted with C1-3 alkyl or OH.
[0111] In certain embodiments, a subset of Formula (I) includes those of Formula (VI):
[0112] wherein R1 and R2 are independently -C2-20 straight or branched alkyl optionally inserted with one or more oxygen (-O-), -C2-20 alkenyl optionally substituted with C1-20 alkyl, -C2-20 alkylene-((CH2)nO)m-Ci-2o alkyl; wherein n and m are independently selected from 1-5, and -C2-10 alkylene-ester-Ci-20 linear or branched alkyl optionally substituted with C1-20 alkyl.
[0113] In some embodiments, R4 and R5 are independently H or C1-3 alkyl, R6 is Ci-4alkyl optionally substituted with OH (e.g.R7 and R8 are independently selected from the group consisting of hydrogen and C1-6 alkyl, wherein R7 and R8 are optionally substituted with OH, NHC1-6 alkyl, or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein RIO52184884579.5Docket No. 084284.00363PCT of 084284.00318 and Rll are independently C1-3 alkyl. Tn some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring.
[0114] In some embodiments, R4 and R5 are independently H, R6 is C1-4 alkyl optionallysubstituted with OH (e.g.R7 and R8 are independently selected from the group consisting of C1-6 alkyl, wherein R7 and R8 are optionally substituted withNHCi-6 alkyl or N(CI-6 alkyl)2, and are optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein RIO and Rll are independently C1-3 alkyl. In some embodiments, R7 and R8 form a C3-6 cycloalkyl ring or 3-6 membered heterocyclic ring.
[0115] In some embodiments, R1 and R2 of any one of Formulas (I), (II), (III), (IV), (V), or (VI) may independently be selected from the following:184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318
[0116] In some embodiments, a subset of compounds of Formulas (I), (II), (III), (IV), (V), or (VI) includes the following structures:56184884579.5Docket No. 084284.00363PCT of 084284.0031857184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.0031860184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.0031864184884579.5Docket No. 084284.00363PCT of 084284.00318
[0117] In another aspect, lipid compounds comprising two compounds of Formula (I) are disclosed herein, according to Formula (VII):(I) (VII)
[0118] wherein the variables are described above with respect to Formula (I). In some embodiments, a first compound of Formula (I) is bonded to a second compound of Formula (I) by a covalent bond between R9 of the first compound of Formula (I) and R9 of the second compound of Formula (I) through a straight or branched C1-20 alkyl chain, optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0119] In some embodiments, as seen in Formula (VIIA), when R9 is N, at least one of R7 or R8 at each Formula (I) is void to complete the nitrogen valency.184884579.5Docket No. 084284.00363PCT of 084284.00318(I) (VIIA)
[0120] In another aspect, lipid compounds comprising three or more compounds of Formula (I) are disclosed herein, according to Formula (VIIB):(Ic) (VIIB)
[0121] wherein R9 is N and wherein k is between 0-20. As seen in Formula (VIIB), the terminal structures Formula (la) and Formula (Ic), e.g., top-most and bottom-most structures, comprise at least one of R7 or R8 as void to complete the nitrogen valency, while R9 equivalent nitrogen in the middle structure (Formula (lb)) does not include any additional substituents, i.e., R7 and R8 are both void.66184884579.5Docket No. 084284.00363PCT of 084284.00318
[0122] In some embodiments, when k is 0, a compound of Formula (la) (e.g., top structure) is bonded to a compound of Formula (Ic) (e.g., bottom structure) by a covalent bond between R9 of the compound of Formula (la) and R9 of the compound of Formula (Ic) through a straight or branched C1-20 alkyl chain, optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
[0123] In some embodiments, when k is greater than 0, the compound of Formula (la) is bonded to a compound of (Ib)k by a covalent bond between R9 of the compound of Formula (la) and R9 of the compound of Formula (Ib)k through a straight or branched C1-20 alkyl chain, optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and the compound of (Ib)k is bonded to the compound of Formula (Ic) by a covalent bond between R9 of the compound of Formula (Ib)k and R9 of the compound of Formula (Ic) through a straight or branched C1-20 alkyl chain, optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH). When k is greater than 1, each Formula (Ib)k structure is bonded to each other between R9 through a straight or branched C1-20 alkyl chain, optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-C 1-20 alkyl, halogen, or (-OH).
[0124] In some embodiments, the lipid compound according to Formula (VII), (VIIA), or (VIIB) may be the following structure:184884579.5Docket No. 084284.00363PCT of 084284.00318Lipid Nanoparticles (LNPs)
[0125] In another aspect, the present disclosure also features a lipid nanoparticle composition comprising a lipid component comprising a compound according to any one of aforementioned Formulas as described herein.
[0126] As used herein, a “lipid component” is that component of a nanoparticle composition that includes one or more lipids. For example, the lipid component may comprise an 68184884579.5Docket No. 084284.00363PCT of 084284.00318 ionizable lipid comprising a compound according to Formula (I), and a helper lipid component including but not limited to one or more PEGylated-lipid, structural-lipid, or phospholipids.
[0127] In some embodiments, the lipid nanoparticle formulation may comprise an aminophosphate-, aminophosphonate-, and aminophosphoramidate-derived lipids (AP lipids) according to any one of aforementioned Formulas, and at least one helper lipid.
[0128] As used herein, the term “Helper lipid” refers to a lipid component of a lipid nanoparticle formulation that is distinct from the cationic or ionizable lipid and that functions to stabilize the lipid nanoparticle structure and / or facilitate intracellular delivery of an associated therapeutic agent, including by modulating membrane properties, promoting lipid phase transitions, or enhancing endosomal escape, without being primarily responsible for electrostatic complexation of the therapeutic agent. In some embodiments, the helper lipid is a neutral or zwitterionic lipid incorporated into a lipid nanoparticle to support particle assembly, structural integrity, and biological performance, including by influencing lipid packing, curvature, fluidity, or membrane fusion behavior. In certain embodiments, the helper lipid contributes to destabilization of the endosomal membrane following cellular uptake, thereby enhancing release of the therapeutic agent into the cytosol.
[0129] In some embodiments, the helper lipid may be a phospholipid, a structural lipid, or a pegylated (i.e., PEG-modified)-lipid. As used herein, the term “PEG lipid” or “pegylated lipid” refers to a lipid comprising a polyethylene glycol component. As used herein, the term “phospholipid” is a lipid that includes a phosphate moiety and one or more carbon chains, e.g., unsaturated fatty acid chains. The phospholipid may comprise one or more multiple (e.g., double or triple bond) bonds (e.g., one or more unsaturated bonds). Certain phospholipids may promote fusion with the membrane. For example, a cationic phospholipid may interact with one or more69184884579.5Docket No. 084284.00363PCT of 084284.00318 negatively charged phospholipids of a membrane (e.g., a cell membrane or an intracellular membrane). The fusion of the phospholipid to the membrane may allow one or more elements of the lipid-containing composition to pass through the membrane, thereby allowing, for example, the delivery of one or more elements to the cell.
[0130] In some embodiments, the phospholipid comprises Dilauroyl lecithin (DLPC), Dimyristoyl phosphatidylcholine (DMPC), Dioleoyl lecithin (DOPC), Dipalmitoyl phosphatidylcholine (DPPC), Distearoyl phosphatidylcholine (DSPC), Dioleoyl phosphatidylcholine (DUPC), Palmitoyl oleoyl phosphatidylcholine (POPC), 1,2-Di-O-octadecyl-sn-glycero-3 -phosphocholine, l-Oleoyl-2-cholesteryldimethylsuccinoyl-sn-glycero-3-phosphocholine, 1 -Hexadecyl-sn-gly cero-3 -phosphocholine, 1,2-Divinyl-sn-glycero-3 -phosphocholine, 1,2-Diarylacyl-sn-glycero-3 -phosphocholine, 1,2-Dioleoyl-sn-glycero-3 -phosphorylethanolamine (DOPE), l,2-Di-phytanoyl-sn-glycero-3 -phosphoethanolamine, 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-Diethenol-sn-gly cero-3 -phosphoethanolamine, 1,2-Divinyl-sn-gly cero-3 -phosphoethanolamine, l,2-Diaryl-sn-glycero-3-phosphoethanolamine, l,2-Dithiohexaenoate-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphate-(l -glycerol) sodium salt (DOPG), and combinations thereof.
[0131] In some embodiments, the structural lipid comprises cholesterol, coprosterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof.
[0132] In some embodiments, the pegylated-lipid comprises 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (DMG-PEG), l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), PEG-disteryl glycerol (DSG-PEG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (DAG-PEG), PEG-dipalmitoyl70184884579.5Docket No. 084284.00363PCT of 084284.00318 phosphatidylethanolamine (DPPE-PEG), or PEG-1, 2-dimyristyloxypropyl-3-amine (DMA-c-PEG), and combinations thereof. In some embodiments, the lipid moiety of the PEG lipids includes those having lengths from about C14 to about C22. In some embodiments, a PEG moiety has a size of about 1000, 2000, 5000, 10,000, 15,000 or 20,000 daltons, i.e., PEG1000, PEG2000, PEG5000, PEG10000, PEG15000, or PEG20000 respectively.
[0133] In some embodiments, the molar ratio between the AP lipid and the helper lipid component (i.e., phospholipid + structural lipid + pegylated lipid) is from about 20 / 200 to about 20 / 40, or about 20 / 180, about 20 / 160, about 20 / 140, about 20 / 120, about 20 / 100, about 20 / 90, about 20 / 80, about 20 / 70, about 20 / 60, about 20 / 50, about 20 / 40, or between any two aforementioned values of AP lipid / helper lipid component.
[0134] In some embodiments, the molar ratio between the AP lipid and phospholipid is from about 20 / 80 to about 20 / 10, about 20 / 70, about 20 / 60, about 20 / 50, about 20 / 40, about 20 / 30, about 20 / 20, about 20 / 10, or between any two aforementioned values of AP lipid / phospholipid.
[0135] In some embodiments, the molar ratio between the AP lipid and structural lipid is from about 20 / 80 to about 20 / 10, about 20 / 70, about 20 / 60, about 20 / 50, about 20 / 40, about 20 / 30, about 20 / 20, about 20 / 10, or between any two aforementioned values of AP lipid / structural lipid.
[0136] In some embodiments, the molar ratio between the AP lipid and pegylated lipid is from about 20 / 2 to about 20 / 0.5, about 20 / 1.75, about 20 / 1.5, about 20 / 1.25, about 20 / 1, about 20 / 0.75, about 20 / 0.5, about 20 / 0.25, or between any two aforementioned values of AP lipid / pegylated lipid.
[0137] In some embodiments, the molar ratio between the AP lipid and each component of the helper lipid (i.e., phospholipid, structural lipid, and pegylated lipid) (AP lipid / phospholipid / structural lipid / pegylated lipid) is from about 20 / 80 / 80 / 2 to about 20 / 10 / 10 / 0.571184884579.5Docket No. 084284.00363PCT of 084284.00318 of AP lipid / pegylated lipid, or any values between therein (e.g., any values encompassed by the following ratio: 1-20 / 5-80 / 5-80 / 0.1-2). In some embodiments, the molar ratio between the AP lipid and each component of the helper lipid (i.e., phospholipid, structural lipid, and pegylated lipid) (AP lipid / phospholipid / structural lipid / pegylated lipid) is from about 20 / 30 / 40 / 0.75 of AP lipid / pegylated lipid.
[0138] In some embodiments, the disclosed LNP further comprises a therapeutic agent. In certain embodiments, the therapeutic agent is encapsulated by the LNP. In some embodiments, the therapeutic agent comprises carbohydrates, protein, lipids, nucleic acids, or combinations thereof. As used herein, the term “nucleic acid” refers to a molecule of two or more nucleotides or alternative nucleotides. The term, “nucleotide” refers to a nucleoside including a phosphate group. The term “nucleoside” refers to a compound containing a sugar molecule (e.g., a pentose or ribose) or derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as a “nucleobase”). Examples of nucleic acids include but are not limited to DNA, RNA, tRNA (transfer RNA), mRNA (messenger RNA), siRNA (small interfering RNA), miRNA (micro-RNA), shRNA (short hairpin RNA), ncRNA (non-coding RNA), aptamers, ribozymes, and shorter oligonucleotide sequences of any of the foregoing. Alterations of the base, sugar, and phosphate moiety of a nucleotide are encompassed by this definition.
[0139] In some embodiments, the therapeutic agent is mRNA. An mRNA may encode any polypeptide of interest, including any naturally or non-naturally occurring or otherwise modified polypeptide. A polypeptide encoded by an mRNA may be of any size and may have any secondary structure or activity. In some embodiments, a polypeptide encoded by an mRNA may have a therapeutic effect when expressed in a cell. In some embodiments, the mRNA encodes a72184884579.5Docket No. 084284.00363PCT of 084284.00318 neurotrophic factor. Tn some embodiments, the mRNA encodes SRY-box transcription factor 2 (Sox2), achaete-scute family bHLH transcription factor 1 (Ascl1), glial cell line-derived neurotrophic factor (GDNF), osteopontin, Insulin-like Growth Factor 1 (IGF-1), Ciliary Neurotrophic Factor (CNTF), Fibroblast Growth Factor 2 (FGF2), Epidermal Growth Factor (EGF), or Brain-Derived Neurotrophic Factor (BDNF). All or a portion of the therapeutic agent nucleic acid may be encapsulated in the lipid nanoparticles. In some embodiments, the LNP may exhibit encapsulation efficiency of at least about 90% (e.g., at least about 85%, at least about 80%, at least about 75%, at least about 70%, at least about 65%, at least about 60%, at least about 55%, at least about 50%).
[0140] In some embodiments, the disclosed LNP may be used for intracellular delivery of a therapeutic agent. In some embodiments, the delivery of the LNP may comprise contacting a cell or administering to a subject a lipid nanoparticle comprising a therapeutically effective amount of a therapeutic agent. In some embodiments, the LNP is administered directly to a spinal cord lesion or the surrounding area. As used herein, the term “subject” encompasses any animal, but preferably a mammal, e.g., a human, non-human primate, a dog, a cat, or a mouse. More preferably, the subject is a human. As used herein, the term “delivery” refers to providing an entity to a target site. For example, delivering a therapeutic and / or prophylactic agent to a subject may include administering a nanoparticle composition containing a therapeutic and / or prophylactic agent to a subject (e.g., by intravenous, intramuscular, intradermal, intrathecal, or subcutaneous routes). Administering a nanoparticle composition to a mammal or mammalian cell may involve contacting one or more cells with the nanoparticle composition. In some embodiments, the target site is a spinal cord lesion.73184884579.5Docket No. 084284.00363PCT of 084284.00318
[0141] In certain embodiments, the lipid nanoparticle (LNP) comprises aminophosphate-, aminophosphonate-, and aminophosphoramidate-derived lipids (AP lipids), phospholipid, structural lipid, and pegylated-lipid as disclosed above. In some embodiments, the AP lipid has a structure of any one of aforementioned Formulas (e.g., Formula (I)) disclosed above. In some embodiments, the phospholipid is DOPE. In some embodiments, the structural lipid is cholesterol. In some embodiments, the pegylated-lipid is DMG-PEG2000. In some embodiments, the therapeutic agent is an mRNA encoding firefly luciferase (FLuc), SRY-box transcription factor 2 (Sox2), achaete-scute family bHLH transcription factor 1 (Ascl1), or glial cell line-derived neurotrophic factor (GDNF).
[0142] In some embodiments, a pharmaceutical composition comprising the present LNP is disclosed herein. The pharmaceutical composition comprises a therapeutically effective amount of at least one therapeutic agent and / or one or more pharmaceutically acceptable excipients, carriers, or diluents. As used herein, the term “pharmaceutically acceptable excipient, carrier, or diluent” includes compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. In some embodiments, the pharmaceutical compositions may be in a form suitable for parenteral administration. Depending upon the therapeutic application, for in vivo administration, the disclosed LNP herein may be administered to a subject in need thereof intravenously, intradermally, intramuscularly, intrathecally, or subcutaneously.
[0143] In some embodiments, the pharmaceutical compositions may be in the form of a sterile injectable aqueous solution or suspension, which may be formulated according to known74184884579.5Docket No. 084284.00363PCT of 084284.00318 procedures. A sterile injectable preparation may also be a sterile injectable suspension in a nontoxic parenterally-acceptable buffer. In other embodiments, the pharmaceutical composition may be lyophilized resulting in the form of a dry powder, wherein the dry powder can be later reconstituted for administration as needed. Dry powder compositions may further comprise bulking agents, for example, sucrose or trehalose.
[0144] Further provided herein is a pharmaceutical kit comprising a pharmaceutical composition comprising the disclosed LNP having a therapeutically effective amount of at least one therapeutic agent. Such kits may further comprise various conventional pharmaceutical kit components such as containers comprising pharmaceutically acceptable adjuvants, diluents, or carriers, and additional containers readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and / or guidelines for mixing the components, can also be included in the kit.
[0145] It will be appreciated by persons skilled in the art that embodiments described herein are not limited to what has been particularly shown and described. Rather, the scope of the invention is defined by the claims which follow. It should further be understood that the above description is only representative of illustrative examples of embodiments. The description has not attempted to exhaustively enumerate all possible variations. That alternate embodiments may not have been presented for a specific component of a nanocarrier, or a step of the method, and may result from a different combination of described constituents, or that un-described alternate embodiments may be available for a composition, kit, or method, is not to be considered a disclaimer of those alternate embodiments. It will be appreciated that many of those un-described embodiments are within the literal scope of the following claims, and others are equivalent.75184884579.5Docket No. 084284.00363PCT of 084284.00318
[0146] As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and / or” unless the content clearly dictates otherwise.
[0147] “Parenteral” administration of an immunogenic composition includes, e.g., subcutaneous, intravenous, intramuscular, intrathecal, or intrasternal injection or infusion techniques.
[0148] The terms “patient” or “individual” or “subject” are used interchangeably herein, and refers to a mammalian subject to be treated, with human patients being preferred. In some cases, the methods of the disclosure find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, hamsters, and primates.
[0149] As used herein, a “pharmaceutically acceptable” component / carrier etc. is one that is suitable for use with humans and / or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit / risk ratio.
[0150] Treatment” is an intervention performed with the intention of preventing the development or altering of the pathology or symptoms of a disorder. Accordingly, “treatment” refers to both therapeutic treatment and prophylactic or preventative measures. “Treatment” may also be specified as palliative care. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. As defined herein, a “therapeutically effective” amount of a compound or agent (i.e., an effective dosage) means an amount sufficient to produce a therapeutically (e g., clinically) desirable result. The compositions can be administered from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity76184884579.5Docket No. 084284.00363PCT of 084284.00318 of the disease or disorder, previous treatments, the general health and / or age of the subject, and other diseases present. Moreover, the treatment of a subject with a therapeutically effective amount of the compounds of the disclosure can include a single treatment or a series of treatments.
[0151] Ranges: throughout this disclosure, various aspects of the disclosure can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, a description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
[0152] Delivery of messenger RNA (mRNA) to the central nervous system (CNS) for treatment of spinal cord injury (SCI) remains challenging. This document provides compositions and methods for efficient and safe delivery of circular RNA encoding therapeutic factors (Sox2, Ascii, and GDNF) that provide a viable therapeutic option for treating SCI.
[0153] To effectively deliver circular RNA encoding these therapeutic factors to the injured spinal cord, both local and systemic delivery methods are essential. Local delivery during surgery allows for direct application to the lesion site, initiating the reprogramming process. Subsequently, systemic delivery can be administered during rehabilitation, providing a neurotrophic effect. Lipid nanoparticles (LNPs) have been utilized to deliver mRNA and circular RNA for various vaccines and therapeutic applications. However, a reliable LNP system specifically for SCI remains to be developed. Phospholipids, essential components of cell77184884579.5Docket No. 084284.00363PCT of 084284.00318 membranes, play a critical role in maintaining the membrane structure and functions. Inspired by natural phospholipids, the present document discloses biomimetic ionizable lipids, such as aminophosphate-, aminophosphonate-, and aminophosphoramidate-derived lipids (AP lipids). These AP lipids are formulated into lipid nanoparticles (LNPs) and examined for their mRNA delivery efficiency in neurons and astrocytes. Furthermore, the present document provides a library of aminophosphate-, aminophosphonate-, and aminophosphoramidate-derived lipid nanoparticles.Intracellular delivery of therapeutic agents
[0154] In another aspect, the present document discloses an integration of circular RNA and delivery vectors to produce a circular RNA-loaded aminophosphonate-derived lipid nanoparticle delivery system (CROSS) that may be used to treat spinal cord injury. This approach combines local applications during surgery to initiate cell reprogramming with subsequent systemic injections to sustain neuroprotection. The CROSS system significantly restored bladder function within two weeks and enhanced locomotor function within six weeks, indicating its use as a therapeutic strategy for SCI recovery.
[0155] In contrast to liposomes and cationic liposomes, lipid nanoparticles have a structure that includes a single monolayer or bilayer of lipids that encapsulates a compound in a solid phase. Thus, unlike liposomes, lipid nanoparticles do not have an aqueous phase or other liquid phase in their interior, but rather the lipids from the bilayer or monolayer shell are directly complexed to the internal compound thereby encapsulating it in a solid core. Lipid nanoparticles are typically spherical vesicles having a relatively uniform dispersion of shape and size ranging from about 10 nm to 1000 nm.78184884579.5Docket No. 084284.00363PCT of 084284.00318
[0156] SCI is a complex condition requiring a multi-step therapeutic approach, involving surgery, anti-inflammatory treatment, and rehabilitation. This document discloses a novel circular RNA-loaded aminophosphonate-derived lipid nanoparticle system (CROSS) for treatment of SCI both locally and intravenously throughout the recovery process. During surgery, LNPs loaded with mRNA encoding one or more neurotrophic factors, for example Sox2 and Ascii, may be delivered directly to the lesion site via local application to promote reprogramming. Post-surgery, weekly intravenous injections of loaded LNPs may be used to help maintain neuron survival and axon regeneration, which are key for restoring bladder function and locomotion.
[0157] The disclosed LNPs incorporate biomimetic ionizable lipids that contain aminophosphonate groups, which improve delivery efficiency in both in vitro and in vivo studies. The incorporation of phosphate groups makes the ionizable lipids more closely mimic natural phospholipids, thereby enhancing interaction with the endosomal membrane and improving the performance of LNPs. The therapeutic factors such as Sox2, Ascii, and GDNF exhibit synergistic roles in neuronal reprogramming and neuroprotection. Sox2 is well known for its role in inducing sternness, pluripotency, and reprogramming, while Ascii, a proneural master regulator, promotes neuronal proliferation and differentiation. The combination of Sox2 and Ascii enhances reprogramming efficiency, generating three times as many induced neurons compared to Sox2 alone. GDNF supports neuron maturation, survival, axon regeneration, and functional recovery. However, prolonged expression of reprogramming factors like Sox2 and GDNF has been associated with cancer progression, making viral vector delivery methods unsuitable due to their potential for long-term expression. The CROSS system described in this disclosure enables controlled expression for 7 to 10 days, allowing for repeated injections as needed and avoiding the risks of long-term overexpression.79184884579.5Docket No. 084284.00363PCT of 084284.00318
[0158] In this disclosure, oligodendrocyte precursor cells (OPCs) were targeted for their potential to differentiate into neurons. However, other cell types, such as astrocytes, microglia, and infiltrating T cells, also play critical roles in SCI repair. Astrocytes, in particular, are essential for repairing both the blood-brain barrier and remodeling tissue, although they can also contribute to glial scar formation, which inhibits axonal growth. Given the dynamic nature of their roles, time-specific interventions are crucial for optimal SCI recovery. The flexibility of the CROSS allows for on-demand modulation of therapeutic factors to address the evolving cellular environment in the injured spinal cord.
[0159] Neurotrophic factors including Sox2, Ascii, GDNF, osteopontin, IGF-1, CNTF, FGF2, EGF, and BDNF are important in axon regeneration, primarily by activating mTOR signaling. In some embodiments, these factors are delivered to both the lesion and surrounding areas for effective recovery. In some embodiments, the present document also integrates systemic injections. Generally, CROSS is flexible in terms of timing, regimens, and delivery routes, allowing it to load various circular RNAs encoding therapeutic factors for SCI treatment.Materials and Methods
[0160] Plasmid construction
[0161] The plasmid was constructed based on previous work disclosed in Zeng, C., et al., Adv Mater (2020) 32 (40), e2004452. The different coding sequences were added into the circRNA-synIRES-R25-mNeonGreen by Gibson assembly. First, the BamHI and Mfel (NEB) were used to cut the plasmid. The firefly luciferase coding sequence, Sox2 coding sequence (a gift from Shinya Yamanaka, pCAG-HA-Sox2, Addgene #13459), ASCL1 coding sequence (a gift from Marius Wernig, pMXs-Ascll, Addgene #134671), and GDNF coding sequence (synthesized by IDT) with 20 bp overlap by PCR (Q5 master mix, NEB) were added into the vector separately.80184884579.5Docket No. 084284.00363PCT of 084284.00318 The assembled mixture was then transformed into 10³ E. coli competent cells. Then, the colonies were selected for sequencing after antibiotic plate selection. All the plasmids were sequenced for further study.
[0162] mRNA and circular RNA Synthesis
[0163] mRNA synthesis followed previously published work disclosed in Xue, Y., et al., Nat Commun (2024) 15 (1), 739. The linear DNA template was prepared by amplifying 1 ng of plasmid DNA using Q5 High-Fidelity DNA Polymerase (New England Biolabs). IVT mRNA synthesis was conducted using HiScribe® T7 High Yield RNA Synthesis Kit (New England Biolabs), with uridine replaced by 1-N-Methyl-Pseudouridine 5'-Triphosphate (Advent Bio). Then, mRNA was purified by RNA Clean & Concentrator (Zymo Research). Subsequently, Faustovirus capping enzyme (New England Biolabs) was used to add the cap-1 to the mRNA. For the traditional circular RNA synthesis method, the linear DNA template was added into the IVT HiScribe® T7 High Yield RNA Synthesis Kit for synthesis of the precursor RNA, with 5% A replaced by m6A. After DNase I digested the DNA template, the RNA was cleaned and concentrated (Zymo Research). Additional GTP and Mg2+were added (2 mM GTP, and T4 RNA Ligase Reaction Buffer, including 50 mM Tris-HCl, 10 mM MgCh, 1 mM DTT, pH 7.5; NEB) for 8 min at 55°C. After circularization, the RNA was column-purified.
[0164] For the high temperature circular RNA synthesis method, the linear DNA template was added to the Hi-T7® RNA Polymerase, and the MgCh was added to 19 mM. The reaction was incubated at 52°C for 4 hours, DNase I was added, and the RNA was column-purified. To purify the circular RNA, 100 pg RNA was treated with 1 pL RNase R (LGC) for 30-60 min. The final mRNA product was purified by RNA Clean & Concentrator again. The final product was quantified using Nanodrop 2000 (Thermo Fisher Scientific) and stored at -80°C for further use.81184884579.5Docket No. 084284.00363PCT of 084284.00318
[0165] Cell assays
[0166] The SH-SY5Y cell line was purchased from ATCC and cultured in DMEM (Corning) with 10% Fetal Bovine Serum (FBS, Corning) and 1 x antibiotic Penicillin-Streptomycin (Gibco). The mouse primary astrocytes and OPCs were isolated and cultured following previously published protocols. Briefly, brains were derived from postnatal day 3 mice, which were placed on ice in Hank's Balanced Salt Solution (HBSS; Gibco, Thermo Fisher Scientific). The cortex was dissociated from the brain and cut into small pieces by a syringe. The remaining tissues were dissected mechanically using a pipet (Fisher). After single cell isolation, the cells were cultured in DMEM containing 10% FBS for 4 h, and then a new culture medium was added.
[0167] As for OPC isolation and culture, they were performed following the protocol disclosed in Li, H., el al., Chemical Engineering Journal (2023) 466, 143152. Briefly, primary mixed glial culture was prepared as described for the primary astrocytes method. The cell culture flasks were pre-coated with poly-L-lysine (PLL, Sigma). The cells were cultured for 8 days in 10% FBS DMEM medium. After that, the flasks were first patted for 5 min to remove the microglia. Then the OPCs were collected in medium after 250 rpm shaking for 6 h at 37°C. As for OPC cell culture, the culture medium contains: DMEM / F12 (1:1, vol / vol) supplemented with 1% N2, 1% B27 (Gibco), 10 ng / ml FGF2 (R& D), and 20 ng / ml EGF (R& D). For differentiation, neuronal differentiation uses differentiation medium (a 1:1 mix of neurobasal medium (NB) and DMEM / F12 supplemented with 1% N2, 1% B27, 200 mM ascorbic acid (Sigma)) and 10 ng / ml BDNF. To generate astrocytes, the differentiation medium contains DMEM / F12 with 10% FBS.
[0168] Primary astrocytes were seeded at 10k cells per well in 96-well plates or 30k cells per well in 24-well plates. SY5Y cells were seeded at a density of 20k cells per well in 96-well plates or 40k cells per well in 24-well plates 12 h prior to treatment. The LNPs were then added to82184884579.5Docket No. 084284.00363PCT of 084284.00318 the wells (for the mRNA dose, 50 ng per well for 96 well plates and 200-300 ng per well for 24 well plates). After 12 h, cells were treated with Bright-Glo luciferase substrate (Promega), and mRNA expression was quantified by bioluminescence intensity through Cytation 5 (Biotek).
[0169] Formulation and characterization of LNP
[0170] LNPs were formulated using the Nano L+ System (Micro& Nano Biologies Technology Ltd.) through a process involving the rapid mixing of an ethanol solution containing ionizable lipids, DOPE, cholesterol, and DMG-PEG2k in specified molar ratios (60:30:40:0.75) with a 10 mM citrate solution (pH 3.0, Fisher) containing mRNA (mass ratio of AP lipid to mRNA is 10: 1). Before use, the LNPs were dialyzed against PBS for 1.5 hours to remove the ethanol. The LNPs' hydrodynamic diameter and zeta potential were assessed using a NanoZS Zetasizer (Malvern). LNP morphology was imaged with the Glacios Cryo-EM (Thermo Scientific) at the Center for Electron Microscopy and Analysis at Ohio State University.
[0171] Spinal cord injury mouse model
[0172] All mouse studies were approved by the Institutional Animal Care and Use Committee (IACUC) at The Icahn School of Medicine at Mount Sinai and complied with state and federal regulations. First, mice are placed under general anesthesia with 1.5% isoflurane in oxy gen-enriched air, and all procedures are performed under microscopy. After placing the mouse on a sterile surgical drape on a heating pad, a 4 cm midline incision is made on the back. Carefully identify the T 10 vertebra. Carefully perform a laminectomy to expose the underlying spinal cord segment without damaging the dura mater. Severe crush spinal cord injury was produced at the level of T10 by using tapered ultrafine tip forceps (Fisher) without spacers to completely compress the entire spinal cord laterally from both sides for 30 seconds. All mice received buprenorphine (0.1 mg / kg, twice a day) for 3 days, ceftriaxone sodium (100 mg / kg, twice per day, Sigma) for 383184884579.5Docket No. 084284.00363PCT of 084284.00318 days to prevent infection, cyclosporin A (2.5 mg / kg, once per day, Sigma) for 7 days to reduce inflammation, and BrdU (50 mg / kg, once a day, Sigma) for 7 days to label the newborn cells.
[0173] Firefly luciferase (Flue) assay in vivo
[0174] Two formulations used AP60-derived LNPs or MC3 LNPs, with mRNA concentrations of 0.1 mg / mL for intravenous (I V.) injection in 150 pL and 0.2 mg / mL for local applications. For local drops, during surgery, carefully expose the lesion site on the spinal cord. Wash the lesion site thoroughly with sterile PBS and use gauze to absorb excess liquid. Apply the LNP solution (0.2 mg / mL, 50 pL total) directly onto the lesion site. Maintain the LNP at the lesion for 15 minutes to allow proper absorption. During the 15-minute waiting period, reapply drops of the LNP solution until the entire volume (50 pL) is used. Then carefully close the lesion by suturing the tissue layer by layer. The mice recover on a heating pad; monitor the mouse until full recovery. After 6 hours, administer D-luciferin (15 mg / mL, Promega) 150-200 pL via I. P. injection, and acquire luminescence intensity by IVIS.
[0175] The Basso-Beattie-Bresnahan (BBB) locomotor rating scale
[0176] The mice were brought to the test environment for 2 hours before scoring to reduce stress. The mice move freely in the open field. Two different observers score the movement. The scoring depends on:
[0177] Score 0: No observable hindlimb movement.
[0178] Score 1: Slight movement of one or two joints.
[0179] Score 2: Extensive movement of one joint.
[0180] Score 3: Extensive movement of two joints.
[0181] Score 4: Slight movement of all three joints.84184884579.5Docket No. 084284.00363PCT of 084284.00318
[0182] Score 5: Slight movement of all three joints and some fore and hindlimb coordination but no weight support.
[0183] Score 6: Extensive movement of all three joints, some fore and hindlimb coordination, but no weight support.
[0184] Score 7: Plantar placement of paw without weight support.
[0185] Score 8: Plantar stepping with occasional weight support.
[0186] Score 9: Frequent or consistent weight-supported plantar steps, no fore and hindlimb coordination.
[0187] Score 10: Occasional fore and hindlimb coordination.
[0188] Score 11: Frequent fore and hindlimb coordination.
[0189] Score 12: Consistent fore and hindlimb coordination.
[0190] Score 13: Consistent fore and hindlimb coordination, consistent plantar steps with paw rotation.
[0191] Score 14: Consistent fore and hindlimb coordination, steps with no paw rotation.
[0192] Score 15: Consistent fore and hindlimb coordination, steps with parallel paw position.
[0193] Score 16: Consistent fore and hindlimb coordination, steps with parallel paw position, and consistent toe clearance.
[0194] Score 17: Consistent fore and hindlimb coordination, and occasional fore and hindlimb coordination loss.
[0195] Score 18: Consistent fore and hindlimb coordination, no forelimb-hindlimb coordination loss, and occasional dorsal stepping.85184884579.5Docket No. 084284.00363PCT of 084284.00318
[0196] Score 19: Consistent fore and hindlimb coordination, consistent plantar steps with parallel paw position, consistent toe clearance, no forelimb-hindlimb coordination loss, consistent toe position with no dorsal stepping.
[0197] Score 20: Consistent fore and hindlimb coordination, consistent toe position with no dorsal stepping, and smooth body movement.
[0198] Score 21: Normal walking, indistinguishable from uninjured mice.
[0199] Immunohistochemistry assays for lesion sites
[0200] Initially, mice were anesthetized and perfused with 20 mb PBS, followed by 20 mb 4% paraformaldehyde (PF A) (Sigma-Aldrich). The spinal cord was removed and maintained in the 4% PFA overnight. Tissues were dehydrated in 20% sucrose, then 30% sucrose. Then the tissues were embedded in OCT (Fisher) for frozen sectioning. Horizontal sections of the whole spinal cord were taken (10 pm thick). The spinal slices were kept at -20°C until staining. For BrdU staining, slices were incubated in 1.5 M HC1 for 15 minutes, then washed three times. The spinal slices were permeabilized with 0.5% Triton for 15 minutes. After washing with PBST, the slices were blocked with donkey serum (Fisher) for 30 minutes at room temperature. Primary antibodies against MAP2, GFAP, NG2, BrdU, MBP, and NF200 (1:200-400, Cell Signaling Technology) were applied and incubated at 4°C overnight. After washing with PBST, secondary antibodies anti-mouse or rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 549 or 488 Conjugate) (1:200, Cell Signaling Technology) were applied and incubated for 1 hour at room temperature. DAPI (Thermo Scientific) was used as a nuclear counterstain. Fluorescence microscopy (Leica Microsystems, DiM8) was applied for all imaging.EXAMPLES86184884579.5Docket No. 084284.00363PCT of 084284.00318
[0201] The present invention is next described by means of the following examples. The use of these and other examples anywhere in the specification is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified form. Likewise, the invention is not limited to any particular preferred embodiments described herein. Indeed, modifications and variations of the invention may be apparent to those skilled in the art upon reading this specification and can be made without departing from its spirit and scope. The invention is therefore to be limited only by the terms of the claims, along with the full scope of equivalents to which the claims are entitled.
[0202] Example 1: Synthesis and characterization of aminophosphate, aminophosphonate, or aminophosphoramidate-derived lipid nanoparticles
[0203] The cell membrane is composed of numerous phospholipids, each containing a hydrophilic head group and two hydrophobic tails. Phospholipids play important roles in cell membrane structure, endocytosis, exocytosis, and many other functions. To mimic the nature of these lipids, three series of ionizable lipids — aminophosphate, aminophosphonate, and aminophosphoramidate-derived (AP) lipids — were designed and synthesized. A representative synthetic route is outlined in the following reaction mechanism.
[0204] The synthesis begins with a transesterification reaction between oleyl alcohol and diphenyl phosphonate. The first series of lipids, exemplified by AP5, that incorporated phosphoramidate or phosphate linkers, was obtained via the Atherton-Todd Reaction, wherein T5-87184884579.5Docket No. 084284.00363PCT of 084284.00318 1 was treated with A4 in the presence of CCU and TEA. The second series of lipids, represented by AP52, were synthesized via a three-component reaction involving dialkyl-H-Phosphonate (T5-1), aldehydes, and amines. The third series of lipids, such as AP60, were produced via an epoxide ring-opening reaction between Al and epoxide TS-2, which was obtained by introducing an epoxide group onto TS1. The chemical structures of these AP lipids were characterized bynuclear magnetic resonance (NMR) and mass spectroscopy (MS). In total, a library of 67 ionizable lipids was obtained for further evaluation of their RNA delivery efficiency.
[0205] Next, these AP lipids were formulated with DOPE, cholesterol, and DMG-PEG together with firefly luciferase (FLuc) mRNA to evaluate mRNA delivery efficiency in SH-SY5Y cells, a neuron cell line, and primary astrocytes. The physicochemical properties including average size and zeta potential of 67 AP LNPs are shown in FIG. 1.
[0206] Seven out of 67 AP LNPs showed dramatically higher luminescence intensity in SY5Y cells and astrocytes. Structure-activity relationship analysis indicates that lipids containing T5 and T7 as the hydrophobic domains exhibit higher delivery efficiency, likely due to the presence of unsaturated bonds and branched tails, respectively. Then, cell viability of AP LNPs was tested by the MTT assay. The best-performing lipid was AP60. The AP60 LNP showed low cytotoxicity in these two cell types as seen in FIG. 2 and good biocompatibility in vivo. Taking into account both delivery efficiency and biosafety, the AP60 LNP was selected for further testing. AP60 LNP loaded with FLuc mRNA was administered to SCI mice both locally and intravenously, using MC3 LNP, an FDA-approved LNP, as the control.
[0207] The AP60 LNP showed a 13.7-fold increase over the MC3 group when dropped locally on the lesion and a 4.6-fold increase when delivered intravenously (FIG. 3). Importantly,88184884579.5Docket No. 084284.00363PCT of 084284.00318 the AP60 LNP exhibited significantly reduced liver expression, nearly 5-fold lower than the MC3 group, as seen in FIG. 2.
[0208] Example 2: Circular RNA synthesis and efficiency in SCI mice
[0209] Typical circular RNA synthesis involves five steps, from IVT to circularization to purification. Circularization of precursor RNA relies on a higher reaction temperature at 55°C, whereas RNA synthesis by polymerase reaction typically occurs at 37°C. A high-temperature-tolerant T7 polymerase was introduced in this study, enabling IVT reactions at 52°C, thereby eliminating the need for buffer exchange and reducing the synthesis steps and purification. To streamline this process, IVT and circularization steps were incorporated into a single step. The circular RNA was efficiently formed from the linear precursor. Agarose gel electrophoresis was used to separate circular and linear RNA. The two methods produced two different lengths of RNA, 2500 bp and 1500 bp, separately. The circular RNA to precursor ratio was 2.1±0.55 in Hi-T7 and 0.91±0.21 in T7 for 2500 bp circular RNA, and 1.64±0.24 in Hi-T7 and 0.84±0.39 in T7 for 1500 bp circular RNA, respectively.
[0210] After synthesis of the circular RNA, the efficiency of the circular RNA was tested in SCI mice. The crush spinal cord injury model was chosen because it closely mimics the mechanical trauma observed in human spinal cord injuries. In this model, the spinal cord is surgically exposed and compressed using forceps, following established protocols. Then, AP60 LNPs loaded with circular or linear FLuc mRNA were locally applied to SCI lesions. Luminescence intensity was similar between linear and circular FLuc mRNA (1.5±0.3x 108vs 1.2±0.08* 108) on day 1. Circular FLuc mRNA maintained high intensity for nearly 5 days, decreasing to 2.2±1.2* 107on day 7, whereas linear FLuc mRNA showed a dramatic decrease from89184884579.5Docket No. 084284.00363PCT of 084284.00318 day 3 (1.5±0.7*107) to day 7 (1.6±0.1 *105). Circular RNA provides sustained luciferase expression in SCI lesions as shown in FIG. 4.
[0211] Example 3: Neurogenesis induced by CROSS in vitro
[0212] Combining the highly effective delivery vector, AP60, with two-step synthesized circular RNAs, the CROSS was developed for both in vitro and in vivo applications. Based on SCI pathology, OPCs accumulated at the lesion to facilitate tissue repair after SCI. These cells can be reprogrammed into neurons by various strategies, such as delivering key factors including Sox2, Ascii, NeuroDl, Neurogenin2, Thrombospondin4, and EGFR inhibitor. According to previous studies, Sox2 and Ascii RNA were used together to achieve higher neurogenesis efficiency, and GDNF was used to support neurogenesis in vivo.
[0213] Circular RNA encoding Sox2, Ascii, and GDNF were produced, and the quality of these RNAs was identified by agarose gel electrophoresis and bioanalyzer. Then, these circular RNAs were formulated with AP60 LNPs and delivered to SH-SY5Y cells. The expression of the corresponding proteins was observed by immunofluorescence staining. OPCs were cultured and identified using the NG2 marker, following a previous study. The AP60 LNP was delivered to OPCs for reprogramming with circular Sox2 and Ascii. The circular GDNF was not included in vitro because the culture medium contained the neurotrophic factors. Map2 and GFAP were stained for neurons and astrocytes, respectively. The AP60 LNP group led to a higher number of neurons than both the untreated control and MC3 LNP (22.0±4.0 cells in control vs. 53.7±11.0 in MC3 vs. 88.0±34.2 in AP60) as seen in FIG. 5. No significant differences were observed among the three groups regarding astrocytic differentiation (85.3±12.6 cells in control vs. 98.3±9.3 in MC3 vs. 91.3±12.1 in AP60) as seen in FIG. 6. Thus, the CROSS with Sox2 and Ascii enables neurogenesis in vitro.90184884579.5Docket No. 084284.00363PCT of 084284.00318
[0214] Example 4: In vivo treatment of SCI with CROSS
[0215] In the SCI model, CROSS, loaded with circular Sox2 and Ascii RNAs, was applied directly to the lesion site during surgery. Subsequently, CROSS with circular GDNF RNA was administered weekly via intravenous injections to facilitate recovery from SCI. Given that bladder dysfunction occurs in nearly 80% of all spinal cord injury patients, residual urine volume was measured using ultrasound to assess bladder function. On Day 1 post-injury, there was no significant difference in residual urine volume between the PBS and CROSS groups (249.4 ± 32.7 mm3vs. 265.8 ± 25.72 mm3). However, after one week of treatment, the residual urine volume decreased to 138.2 ± 36.0 mm3in the CROSS group, compared to 225.7 ± 38.5 mm3in the PBS group. By the end of two weeks, bladder function had nearly recovered in the CROSS group, with residual urine of only 61.7 ± 27.6 mm3, compared to 43.28 ± 20.5 mm3in healthy mice(p>0.05). In contrast, the PBS group showed residual urine volume of 193.9 ± 28.2 mm3.
[0216] These results showed that the CROSS treatment enabled the recovery of bladder function. Meanwhile, locomotor function, another critical biomarker of SCI, was assessed using the Basso-Beattie-Bresnahan (BBB) locomotor rating scale. Immediately following SCI, the mice showed minimal hind limb movement (Score 1.8± 1.6 in the PBS group vs. 1.8± 1.2 in the CROSS group, p>0.05). After 4 weeks, locomotor performance of mice in the CROSS group was significantly improved (14.3 ± 1.8) compared to the PBS group (11.3=1=2.1). The CROSS group demonstrated locomotion with consistent weight-bearing stepping, while the PBS group displayed only occasional coordination. By week 6, the CROSS-treated mice achieved near-normal locomotion with a score of 17.0 ± 3.0, while the PBS group showed limited progress (11.2 ± 2.9).
[0217] Histological analysis of the spinal cord lesion was performed at week 6 post-injury. In the CROSS-treated samples, enhanced proximity of neuron (Map2) growth to the glial scar91184884579.5Docket No. 084284.00363PCT of 084284.00318 (GFAP) border was observed compared to controls. After neurogenesis, the neurotrophic factor resulted in myelination and axon formation. Myelin basic protein (MBP) and neurofilament heavychain protein (NF200) were stained to identify the myelin and axons. The myelin sheath and axons in the CROSS group showed more signal than those in the PBS group. The CROSS treatment can contribute to axon regrowth and function. To identify newly generated neurons after SCI, mice received Bromodeoxyuridine (BrdU), a thymidine analog that incorporates into DNA during cell proliferation. The Map2+and BrdU+double-positive cells in immunofluorescent images indicated new neurons. Co-localization of Map2+(Green) and BrdU+(Red) cells on the border of the lesion was observed, and new neurons in the CROSS group were much more numerous than those in the PBS group (8.9±4.7 cells in PBS vs. 27.7±11 cells in CROSS, p<0.01).
[0218] Example 5: General procedure for the synthesis of dialkyl -H-phosphonates (compound 8-15)
[0219] Alcohol (6.15 mmol) was added to a solution of 0.7 g (3.0 mmol) diphenyl phosphonate in 3.0 mL of pyridine. The mixture was heated to 75°C and maintained for 3 hours. Pyridine was removed under reduced pressure. The resulting mixture was diluted with 100 mL of DCM, washed with 10 mL of 1 N NaOH and 10 mL of water. The organic phase was dried with Na2SO4, filtered, and the solvent was removed again under reduced pressure. The residue was purified by silica gel chromatography with an elution gradient of 0%-10% ethyl acetate in hexane, yielding the desired products.
[0220] Example 6: General procedure for synthesis of aminophosphate and aminophosphoramidate lipids (AP1-AP51)
[0221] To a flame-dried flask containing Dialkyl-H-Phosphonates (0.35 mmol) and carbon tetrachloride (2.0 mL) was added dropwise a solution of triethylamine (194.6 pL, 1.4 mmol),92184884579.5Docket No. 084284.00363PCT of 084284.00318 DMAP (4.3 mg, 0.035 mmol), and amino alcohols or amines (2.0 mmol) in 1.0 mL of dry DCM under vigorous stirring at RT. The reaction mixture was stirred for 1 hour, diluted with 50 mL of DCM, and washed three times with 50 mL of brine. The organic phase was isolated, dried over anhydrous Na2SO4, fdtered, and the solvent was removed in vacuo. The residue was purified via silica gel chromatography (0% - 20% [mixture of 3% NH4OH, 22% MeOH in dichloromethane] in dichloromethane) to give the desired products.
[0222] Hl NMR Data of compounds of Examples 5 and 6 are shown below:
[0223] Compound 14.rH NMR (300 MHz, CDCh) 86.80 (d, J= 692.1 Hz, 1H), 4.66 (s, 4H), 4.05 (dtd, J= 8.4, 6.6, 1.9 Hz, 4H), 3.51 (t, J= 6.6 Hz, 8H), 1.74- 1.63 (m, 4H), 1.62 - 1.52 (m, 8H), 1.42 - 1.26 (m, 29H), 0.92 - 0.84 (m, 6H).31P NMR (121 MHz, CDCh) 87.90.
[0224] Compound 15.1HNMR(300 MHz, CDCh) 86.80 (d, J= 692.7 Hz, 1H), 4.06 (td, J= 6.5, 2.2 Hz, 8H), 2.30 (tt, J= 8.9, 5.3 Hz, 2H), 1.63 (tt, J= 21.5, 7.8 Hz, 13H), 1.41 (ddt, J = 10.4, 6.7, 3.9 Hz, 13H), 1.25 (t, J= 2.5 Hz, 41H), 0.86 (d, J = 6.9 Hz, 12H).31P NMR (121 MHz, CDC13) 87.86.184884579.5Docket No. 084284.00363PCT of 084284.00318
[0225] API. ' H NMR (300 MHz, CDCI3) 84.13 (dt, J = 7.6, 6.0 Hz, 2H), 4.03 (q, J = 6.9 Hz, 4H), 2.63 (t, J = 6.0 Hz, 2H), 2.30 (s, 6H), 1.67 (p, J = 6.6 Hz, 4H), 1.38 - 1.25 (m, 28H), 0.88 (t, J = 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 6 -0.24.
[0226] AP2. 'H NMR (300 MHz, CDCh) 84.13 (dt, J= 7.5, 6.0 Hz, 2H), 4.03 (q, J = 6.6 Hz, 4H), 2.63 (t,. / 60 Hz, 2H), 2.31 (s, 6H), 1.67 (p,. / - 6.6 Hz, 4H), 1.43 - 1.18 (m, 36H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 -0.40.
[0227] AP3. 'H NMR (300 MHz, CDCh) 84.13 (dt, J = 1.6, 6.0 Hz, 2H), 4.03 (q, J = 6.6 Hz, 4H), 2.63 (t, J =6.0 Hz, 2H), 2.31 (s, 6H), 1.67 (p, J= 6.6 Hz, 4H), 1.38 - 1.25 (m, 44H), 0.88 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 -0.24.
[0228] AP4.JH NMR (300 MHz, CDCh) 84.13 (q, J= 6.3 Hz, 2H), 4.03 (q, J= 6.9 Hz, 4H), 2.62 (t, J= 6.0 Hz, 2H), 2.30 (s, 6H), 1.68 (q, J= 6.9 Hz, 4H), 1.36 - 1.25 (m, 52H), 0.88 (m, 6H).31P NMR (121 MHz, CDCh) 8 -0.23.
[0229] AP5. 'H NMR (300 MHz, CDCh) 85.47 - 5.26 (m, 4H), 4.13 (dt, J= 7.5, 6.0 Hz, 2H), 4.03 (q, J= 6.9 Hz, 4H), 2.63 (t, J= 6.0 Hz, 2H), 2.30 (s, 6H), 2.00 (t, J= 6.3 Hz, 8H), 1.68 (q, J= 6.9 Hz, 4H), 1.38 - 1.25 (m, 44H), 0.88 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 -0.24.94184884579.5Docket No. 084284.00363PCT of 084284.00318
[0230] AP6. 'H NMR (300 MHz, CDCh) 85.50 - 5.26 (m, 8H), 4.12 (dt, J= 7.4, 6.0 Hz, 2H), 4.03 (q, J= 6.7 Hz, 4H), 2.77 (t, J= 6.0 Hz, 4H), 2.61 (t, J= 6.0 Hz, 2H), 2.29 (s, 6H), 2.05 (q, J = 6.6 Hz, 8H), 1.67 (t, J = 7.2 Hz, 4H), 1.41 - 1.22 (m, 32H), 0.89 (t, J = 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 6 -0.24. HRMS (w / z): [M+H]+calcd. for C40H77NO4P, 666.5585; found: 666.5594.
[0231] AP7. 'H NMR (300 MHz, Chloroform-; / ) 8 4.13 - 3.81 (m, 4H), 3.31 - 3.11 (m, 1H), 2.95 (dq, J= 8.1, 6.0 Hz, 2H), 2.37 (t, J= 5.7Hz, 2H), 2.21 (s, 6H), 1.70- 1.61 (m, 4H), 1.39 - 1.18 (m, 28H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, Chloroform-^ 89.742.
[0232] AP8. 'HNMR (300 MHz, Chloroform-^) 8 4.13 - 3.79 (m, 4H), 3.34 - 3.11 (m, 1H), 2.95 (dq, J= 8.1, 6.0 Hz, 2H), 2.45 - 2.29 (m, 2H), 2.21 (s, 6H), 1.66 (p, J= 6.6 Hz, 4H), 1.40 - 1.21 (m, 36H), 0.86 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, Chloroform-; / ) 89.447.
[0233] AP9. 'H NMR (300 MHz, Chloroform-; / ) 8 4.12 - 3.86 (m, 4H), 3.28 - 3.14 (m, 1H), 2.95 (dq, J = 7.8, 6.0Hz, 2H), 2.36 (t, J= 6.0Hz, 2H), 2.21 (s, 6H), 1.70- 1.61 (m, 4H), 1.47 - 1.13 (m, 44H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, Chloroform-; / ) 89.467.95184884579.5Docket No. 084284.00363PCT of 084284.00318
[0234] AP10. 'H NMR (300 MHz, Chloroform-; / ) 53.96 (qq, J= 6.6, 3.3 Hz, 4H), 3.23 (dt, J = 11.7, 6.0 Hz, 1H), 2.94 (dq, J= 8.1, 6.0 Hz, 2H), 2.36 (t, J= 6.0 Hz, 2H), 2.20 (s, 6H), 1.65 (p, J= 6.6 Hz, 4H), 1.24 (s, 52H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, Chloroform-d) 59.62.
[0235] AP11. 'H NMR (300 MHz, Chloroform-; / ) 85.63 - 5.07 (m, 4H), 4.11 - 3.79 (m, 4H), 3.23 (dt, J= 11.4, 6.0 Hz, 1H), 3.05 - 2.83 (m, 2H), 2.37 (t, J= 6.0 Hz, 2H), 2.21 (s, 6H), 2.12 - 1.77 (m, 8H), 1.66 (p, J= 6.9 Hz, 4H), 1.44 - 1.18 (m, 45H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 89.556.
[0236] AP12.rH NMR (300 MHz, Chloroform-; / ) 85.52 - 5.14 (m, 8H), 4.22 - 3.71 (m, 4H), 3.36 - 3.07 (m, 1H), 3.03 - 2.88 (m, 2H), 2.77 (t, J= 6.0 Hz, 4H), 2.37 (t, J= 6.0 Hz, 2H), 2.21 (s, 6H), 2.05 (q,.7= 6.6 Hz, 8H), 1.69 - 1.62 (m, 4H), 1.40 - 1.21 (m, 33H), 0.88 (t,.7= 6.6 Hz, 6H).31P NMR (121 MHz, CDCI3) 89.707.
[0237] AP13.JH NMR (400 MHz, Chloroform-; / ) 84.60 (s, 4H), 4.02 -3.83 (m, 4H), 3.57 - 3.38 (m, 8H), 3.37 - 3.24 (m, 1H), 3.02 - 2.92 (m, 2H), 2.38 (t, J= 5.6 Hz, 2H), 2.21 (s, 6H), 1.72 - 1.42 (m, 12H), 1.39 - 1.13 (m, 28H), 0.83 (t, J= 5.6 Hz, 6H).96184884579.5Docket No. 084284.00363PCT of 084284.00318
[0238] AP14. 'H NMR (400 MHz, Chloroform-t / ) 84.26 - 3.85 (m, 8H), 3.42 - 3.25 (m, 2H), 3.13 - 2.87 (m, 2H), 2.85 - 2.55 (m, 5H), 2.40 - 2.24 (m, 2H), 1.75 - 1.53 (m, 12H), 1.52 -1.00 (m, 52H), 0.97 - 0.76 (m, 12H).
[0239] AP15. 'H NMR (300 MHz, CDCh) 8 4.12 - 4.05 (m, 2H), 4.05 - 3.97 (m, 4H), 2.39 (t, 7 = 7.2 Hz, 2H), 2.24 (s, 6H), 1.85 (p, = 6.6Hz, 2H), 1.68 (q, J= 6.9Hz, 4H), 1.38 - 1.25 (m, 28H), 0.88 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 -0.24.
[0240] AP16. 'H NMR (300 MHz, Chloroform-c / ) 84.15 - 4.06 (m, 2H), 4.02 (q, J = 6.9 Hz, 4H), 2.39 (t, J= 7.2 Hz, 2H), 2.24 (d, J= 1.5 Hz, 6H), 1.86 (p, J= 6.6 Hz, 2H), 1.67 (p, J = 6.6 Hz, 4H), 1.36 - 1.25 (m, 36H), 0.88 (t, J= 7.2 Hz, 6H).31P NMR (121 MHz, CDCh) 8 -0.39.
[0241] AP17.rH NMR (300 MHz, Chloroform-tT) 84.14 - 4.05 (m, 2H), 4.05 - 3.96 (m, 4H), 2.44 - 2.33 (m, 2H), 2.24 (d, J= 1.2 Hz, 6H), 1.86 (p, J= 6.6 Hz, 2H), 1.68 (q, J= 6.9 Hz, 4H), 1.38 - 1.25 (m, 44H), 0.88 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 -0.25.97184884579.5Docket No. 084284.00363PCT of 084284.00318
[0242] APIS. ‘HNMR (300 MHz, Chloroform-^ 84.14 - 4.05 (m, 2H), 4.05 - 3.95 (m, 4H), 2.48 - 2.33 (m, 2H), 2.23 (s, 6H), 1.93 - 1.78 (m, 2H), 1.68 (q, J = 6.9 Hz, 4H), 1.38 - 1.25 (m, 52H), 0.87 (t, 6.6 Hz, 6H).31PNMR(121 MHz, CDCh) 8 -0.39.
[0243] AP19. 'H NMR (300 MHz, Chloroform-d) 85.44 - 5.25 (m, 4H), 4.13 - 4.05 (m, 2H), 4.05 - 3.98 (m, 4H), 2.40 (t, J= 7.5 Hz, 2H), 2.25 (s, 6H), 2.00 (t, J= 6.3 Hz, 7H), 1.87 (p, J = 6.9 Hz, 2H), 1.68 (q, J= 6.9 Hz, 4H), 1.44 - 1.18 (m, 44H), 0.88 (t, J= 6.6 Hz, 6H).31PNMR (121 MHz, CDCh) 8 -0.20.
[0244] AP20. 'H NMR (300 MHz, Chloroform-t / ) 85.45 - 5.26 (m, 8H), 4.15 - 4.05 (m, 2H), 4.05 - 3.96 (m, 4H), 2.77 (t, J= 6.0 Hz, 4H), 2.36 (t, J= 7.2 Hz, 2H), 2.22 (s, 6H), 2.05 (q, J = 6.6 Hz, 8H), 1.84 (p, J= 6.9 Hz, 2H), 1.73 - 1.63 (m, 4H), 1.39 - 1.22 (m, 32H), 0.89 ((t, J = 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 -1.7. HRMS (w / z): [M+H]+calcd. for C4IH79NO4P+, 680.5741; found: 680.5748.
[0245] AP21. 'H NMR (300 MHz, Chloroform-c / ) 83.96 (qd, J= 6.6, 3.0 Hz, 4H), 3.51 (dt, J= 12.3, 6.3 Hz, 1H), 2.98 (dq, J= 9.6, 6.3 Hz, 2H), 2.37 (t, J= 6.6 Hz, 2H), 2.22 (s, 6H), 1.65 (ddt, J= 11.5, 6.9, 4.2 Hz, 6H), 1.31 - 1.24 (m, 28H), 0.87 (t, J= 6.6Hz, 6H).31PNMR(121 MHz, CDCh) 89.61.98184884579.5Docket No. 084284.00363PCT of 084284.00318
[0246] AP22. 'H NMR (300 MHz, Chloroform-tZ) 53.98 (qd, J= 6.6, 3.0 Hz, 4H), 3.53 (dt, J= 12.0, 6.6 Hz, 1H), 3.00 (dq, J= 9.6, 6.6 Hz, 2H), 2.38 (t, J= 6.6 Hz, 2H), 2.24 (s, 6H), 1.67 (ddt, J = 9.6, 6.6, 4.8 Hz, 6H), 1.46 - 1.18 (m, 36H), 0.90 (t, J = 6.6 Hz, 6H).31PNMR (121 MHz, CDCh) 89.58.
[0247] AP23. 'H NMR (300 MHz, Chloroform-d) 83.96 (qd, J = 6.6, 3.3 Hz, 4H), 3.51 (dt, J= 12.0, 6.0 Hz, 1H), 2.98 (dq, J= 9.6, 6.6 Hz, 2H), 2.37 (dd, J= 7.5, 5.7 Hz, 2H), 2.22 (t, J = 1.2 Hz, 6H), 1.71 - 1.58 (m, 6H), 1.38 - 1.25 (m, 44H), 0.88 (q, J= 6.6, Hz, 6H).31PNMR (121 MHz, CDCh) 89.58.
[0248] AP24. 'H NMR (300 MHz, Chloroform-c / ) 83.96 (qd, J = 6.6, 3.3 Hz, 4H), 2.98 (dq, J= 9.6, 6.6 Hz, 2H), 2.36 (t, J= 6.6 Hz, 2H), 2.21 (s, 6H), 1.64 (ddt, J= 9.6, 6.6, 3.9 Hz, 6H), 1.31 - 1.25 (m, 52H), 0.87 (t,,7= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 89.69.
[0249] AP25. 'HNMR (300 MHz, Chloroform-^ 85.43 - 5.26 (m, 2H), 3.96 (qd, J= 6.6, 3.0 Hz, 2H), 2.98 (dq,,7 = 9.6, 6.3 Hz, 1H), 2.36 (t,.7= 6.6 Hz, 1H), 2.22 (s, 3H), 1.99 (t, J= 6.3 Hz, 4H), 1.64 (ddt, J= 9.3, 6.6, 3.3 Hz, 3H), 1.32 - 1.25 (m, 22H), 0.87 (t, J= 6.6 Hz, 3H).31P NMR (121 MHz, CDCh) 89.68.99184884579.5Docket No. 084284.00363PCT of 084284.00318
[0250] AP26.JHNMR (300 MHz, Chloroform-t / ) 85.46 - 5.25 (m, 8H), 3.96 (qd, J= 6.9, 2.7 Hz, 4H), 3.53 (dt, J= 12.0, 6.3 Hz, 1H), 2.98 (dq, J= 9.6, 6.3 Hz, 2H), 2.77 (t, J= 6.0 Hz, 4H), 2.34 (t, J= 6.6 Hz, 2H), 2.20 (s, 6H), 2.04 (q, J= 6.6 Hz, 8H), 1.64 (q, J= 7.2 Hz, 6H), 1.41 - 1.22 (m, 32H), 0.89 (t, J = 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 9.69. HRMS (m / z):[M+H]+calcd. for C4iH8oN203P+, 679.5901; found: 679.5908.
[0251] AP27.1HNMR(400MHz, Chloroform-t / ) 84.62 (s, 4H), 4.03 -3.81 (m, 4H), 3.65 - 3.38 (m, 9H), 3.00 - 2.87 (m, 2H), 2.37 (d, J= 7.6 Hz, 2H), 2.22 (s, 6H), 1.68 - 1.45 (m, 14H), 1.39 - 1.16 (m, 28H), 0.91 - 0.76 (m, 6H).
[0252] AP28. ‘H NMR (400 MHz, Chloroform-d) 84.08 - 3.82 (m, 8H), 3.44 - 3.34 (m, 1H), 3.10 - 2.88 (m, 2H), 2.60 - 2.56 (m, 1H), 2.40 - 2.32 (m, 5H), 2.32 - 2.20 (m, 2H), 1.77 -1.46 (m, 14H), 1.43 - 1.31 (m, 12H), 1.30 - 1.12 (m, 40H), 0.89 - 0.76 (m, 12H).
[0253] AP29. ’H NMR (400 MHz, Chloroform-^ 84.59 (s, 4H), 3.85 (dq, J = 16.4, 8.0 Hz, 4H), 3.51 - 3.39 (m, 8H), 2.98 (q, J= 8.4 Hz, 2H), 2.58 (d, J= 9.6 Hz, 3H), 2.33 - 2.24 (m, 2H), 2.21 (s, 6H), 1.73 - 1.46 (m, 14H), 1.38 - 1.13 (m, 28H), 0.81 (t, J= 7.2 Hz, 6H).184884579.5Docket No. 084284.00363PCT of 084284.00318
[0254] AP30. 'H NMR (400 MHz, Chloroform-; / ) 84.01 (q, J = 5.6, 5.0 Hz, 4H), 3.96 - 3.79 (m, 4H), 3.55 - 3.46 (m, 1H), 3.18 - 2.96 (m, 3H), 2.60 (dd, J= 9.6, 4.0 Hz, 3H), 2.34 (d, J = 6.4 Hz, 2H), 2.26 (d, J= 3.6 Hz, 6H), 1.77 - 1.45 (m, 14H), 1.44 - 1.13 (m, 52H), 0.94 - 0.72 (m, 12H).
[0255] AP31. 'H NMR (300 MHz, Chloroform-^ 83.96 (qd, J= 6.6, 3.9 Hz, 4H), 3.09 - 2.95 (m, 1H), 2.90 (dq, J= 9.6, 6.3 Hz, 2H), 2.30 - 2.23 (m, 2H), 2.20 (s, 6H), 1.66 (q, J= 6.9 Hz, 4H), 1.50 (dq, J= 6.6, 3.7, 3.2 Hz, 4H), 1.37 - 1.24 (m, 28H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCI3) 59.67.
[0256] AP32. 'H NMR (300 MHz, Chloroform-; ) 83.96 (qd, J = 6.6, 3.9 Hz, 4H), 2.99 (dd, J= 10.5, 6.6 Hz, 1H), 2.90 (dq, J = 9.6, 6.3 Hz, 2H), 2.33 - 2.22 (m, 2H), 2.21 (s, 6H), 1.67 (q, J = 6.9 Hz, 4H), 1.50 (dq, J = 6.6, 3.9, 3.3 Hz, 4H), 1.35 - 1.25 (m, 36H), 0.87 (t, J= 6.6Hz, 6H).31PNMR(121 MHZ, CDCh) 59.61.
[0257] AP33. 'H NMR (300 MHz, Chloroform-; / ) 83.96 (qd, J = 6.6, 4.0 Hz, 4H), 3.09 - 2.96 (m, 1H), 2.90 (dq, J = 9.6, 6.3 Hz, 2H), 2.21 (s, 8H), 1.67 (q, J = 6.9 Hz, 4H), 1.50 (dq, J =101184884579.5Docket No. 084284.00363PCT of 084284.00318 6.6, 3.6, 3.0 Hz, 4H), 1.35 - 1.25 (s, 44H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 89.74.
[0258] AP34. ' H NMR (300 MHz, Chloroform-; / ) 83.99 (qd, J = 6.6, 4.2 Hz, 4H), 2.93 (dq, J= 12.6, 6.3, 5.2 Hz, 3H), 2.37 - 2.27 (m, 2H), 2.25 (s, 6H), 1.72- 1.63 (m, 4H), 1.54 (p, J = 3.6 Hz, 4H), 1.38 - 1.27 (m, 52H), 0.90 (t, J= 6.6Hz, 6H).31PNMR (121 MHz, CDCh) 89.71.
[0259] AP35. 'H NMR (300 MHz, Chloroform-; / ) 85.52 - 5.22 (m, 4H), 4.05 - 3.87 (m, 4H), 3.09 - 2.96 (m, 1H), 2.96 -2.83 (m, 2H), 2.26 (t, J= 6.6 Hz, 2H), 2.21 (s, 6H), 2.11 - 1.84 (m, 8H), 1.65 (t, J= 7.2 Hz, 4H), 1.57 - 1.47 (m, 4H), 1.38 - 1.16 (m, 44H), 0.86 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 89.760.
[0260] AP36. 'H NMR (300 MHz, Chloroform-; / ) 85.53 - 5.18 (m, 8H), 4.06 - 3.87 (m, 4H), 2.94 - 2.88 (m, 1H), 2.77 (t, J= 6.3 Hz, 4H), 2.29 - 2.23 (m, 2H), 2.21 (s, 6H), 2.04 (q, J = 6.6 Hz, 8H), 1.65 (h, J= 6.6 Hz, 4H), 1.55 - 1.46 (m, 4H), 1.40 - 1.22 (m, 32H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 89.511.
[0261] AP37. 'H NMR (400 MHz, Chloroform-^) 54.61 (s, 4H), 3.90 (q, J= 5.6, 5.2 Hz, 4H), 3.46 (q, J= 5.6 Hz, 8H), 3.17 - 2.93 (m, 2H), 2.94 - 2.74 (m, 2H), 2.29 - 2.17 (m, 7H), 1.67 - 1.40 (m, 16H), 1.26 (d, J= 10.8 Hz, 28H), 0.95 -0.70 (m, 6H).102184884579.5Docket No. 084284.00363PCT of 084284.00318
[0262] AP38. 'H NMR (400 MHz, Chloroform-^) 84.07 - 3.98 (m, 4H), 3.98 - 3.83 (m, 4H), 3.52 - 3.42 (m, 1H), 3.16 - 2.85 (m, 4H), 2.47 - 2.31 (m, 2H), 2.28 (s, 6H), 1.74 - 1.44 (m, 16H), 1.45 - 1.32 (m, 12H), 1.31 - 1.10 (m, 40H), 0.93 - 0.75 (m, 12H).
[0263] AP39. 'H NMR (300 MHz, Chloroform-; / ) 84.00 - 3.81 (m, 4H), 3.08 - 2.96 (m, 4H), 2.26 (t, J= 7.5 Hz, 4H), 2.22 (s, 12H), 1.68 (ddd, J= 24.3, 11.4, 6.6 Hz, 8H), 1.34 - 1.25 (m, 28H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 89.60.
[0264] AP40. ’H NMR (300 MHz, Chloroform-^ 84.00 - 3.80 (m, 4H), 3.01 (ddd, J = 11.1, 8.7, 6.6 Hz, 4H), 2.24 (dd, J= 8.4, 6.3 Hz, 4H), 2.20 (s, 12H), 1.67 (tt, J= 14.1, 6.3 Hz, 8H), 1.29 -1.25 (m, 36H), 0.87 (t, J= 6.6 Hz, 6H).103184884579.5Docket No. 084284.00363PCT of 084284.00318
[0265] AP41 'H NMR (300 MHz, Chloroform-^ 84.02 - 3.80 (m, 4H), 3.09 - 2.95 (m, 4H), 2.20 (s, 16H), 1.66 (dp, J= 13.8, 7.5, 6.9 Hz, 8H), 1.33 - 1.25 (m, 44H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 10.89.
[0266] AP42.rH NMR (300 MHz, Chloroform-d) 84.01 - 3.81 (m, 4H), 3.10 - 2.94 (m, 4H), 2.29-2.22 (m, 4H), 2.21 (s, 12H), 1.68 (tt, J= 14.1, 6.3 Hz, 8H), 1.33 - 1.25 (m, 52H), 0.87 (t,. / = 6,6 Hz, 6H).
[0267] AP43. 'H NMR (300 MHz, Chloroform -o') 8 5.34 (td, J = 6.0, 5.4, 3.3 Hz, 4H), 3.98 - 3.81 (m, 4H), 3.10 - 2.95 (m, 4H), 2.51 -2.13 (m, 16H), 1.99 (p, J= 8.1, 7.2 Hz, 8H), 1.66 (dq, J= 20.7, 7.1 Hz, 8H), 1.36 - 1.24 (m, 48H), 0.87 (t, J= 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 8 10.67.
[0268] AP44. 'H NMR (300 MHz, Chloroform-r / ) 85.46 - 5.25 (m, 8H), 4.00 - 3.81 (m, 4H), 3.13 - 2.90 (m, 4H), 2.77 (t, J = 6.0 Hz, 4H), 2.24 (dd, J= 8.4, 6.3 Hz, 4H), 2.21 (s, 12H), 2.04 (q, J= 6.6 Hz, 8H), 1.66 (tt, J= 12.9, 7.2 Hz, 8H), 1.38 - 1.23 (m, 32H), 0.89 (t, J= 6.6 Hz,184884579.5Docket No. 084284.00363PCT of 084284.00318 6H).31P NMR (121 MHz, CDCh) 8 11.01. HRMS (m / z. [M+H]+calcd. for C46H9iN3O3P+, 764.6793; found: 764.6802.
[0269] AP45.1HNMR(400MHz, Chloroform-tZ) 84.64 (s, 4H), 4.02-3.71 (m, 4H), 3.59 - 3.42 (m, 8H), 3.41 - 3.18 (m, 2H), 3.10 - 2.88 (m, 4H), 2.34 - 2.22 (m, 14H), 1.81 - 1.48 (m, 16H), 1.40 - 1.18 (m, 28H), 0.93 - 0.80 (m, 6H).
[0270] AP46.1HNMR(400 MHz, Chloroform-tT) 84.26 - 3.66 (m, 10H), 3.66 - 2.85 (m, 6H), 2.64 - 1.94 (m, 14H), 1.68 - 1.10 (m, 68H), 0.87 - 0.71 (m, 12H).
[0271] AP47. 'H NMR (300 MHz, Chloroform-c / ) 8 4.05 (qd, J = 6.6, 6.0, 1.5 Hz, 6H), 3.66 - 3.52 (m, 4H), 2.77 (t, J= 4.5 Hz, 2H), 2.70 - 2.53 (m, 4H), 1.65 (q, J= 6.9 Hz, 4H), 1.36 -1.25 (m, 28H), 0.92 - 0.79 (m, 6H).31P NMR (121 MHz, CDCh) 80.69.105184884579.5Docket No. 084284.00363PCT of 084284.00318
[0272] AP48 ‘HNMR (300 MHz, Chloroform-t / ) 84.14 - 4.00 (m, 6H), 3.59 (t, J = 4.8 Hz, 4H), 2.80 -2.73 (m, 2H), 2.71 -2.62 (m, 4H), 1.66 (q, J = 6.9 Hz, 4H), 1.35 - 1.25 (m, 36H), 0.88 (t, 6.6 Hz, 6H).31P NMR (121 MHz, CDCh) 80.84.
[0273] AP49. 'H NMR (300 MHz, Chloroform-t / ) 84.16 - 4.02 (m, 6H), 3.61 (t, J = 4.8 Hz, 4H), 2.85 - 2.73 (m, 2H), 2.68 (dd, J = 5.1, 3.9 Hz, 4H), 1.69 (t, J = 1.1 Hz, 4H), 1.35 - 1.27 (m, 44H), 0.89 (t, J= 6.6 Hz, 6H).31PNMR(121 MHz, CDCh) 8 1.03.
[0274] AP50. 'H NMR (300 MHz, Chloroforms / ) 84.05 (q, J= 6.9 Hz, 6H), 3.59 (t, J = 4.8 Hz, 4H), 2.77 (t, J= 4.5 Hz, 2H), 2.65 (t, J= 4.8 Hz, 4H), 1.67 (p, J= 6.6 Hz, 4H), 1.38 - 1.25 (m, 52H), 0.87 (t, J= 6.4 Hz, 6H).31P NMR (121 MHz, CDCh) 80.86.
[0275] AP51.31P NMR (121 MHz, CDCh) 80.69. ’H NMR (400 MHz, Chloroforms / ) 8 5.45 - 5.25 (m, 8H), 4.14 - 4.00 (m, 6H), 3.59 (t, J= 4.8 Hz, 4H), 2.77 (dd, J= 7.8, 5.4 Hz, 6H), 2.70 -2.61 (m, 4H), 2.04 (q,.7= 6.8 Hz, 8H), 1.67 (q,.7= 6.9 Hz, 4H), 1.39 - 1.21 (m, 32H), 0.89 (t, J= 6.7 Hz, 6H).
[0276] AP52. To a round bottom flask equipped with a stirring bar was added 4 mL of THF, dimethylamine (1.0 mmol), and 37% formaldehyde (0.082 mL, 1.1 mmol), after stirring for 106184884579.5Docket No. 084284.00363PCT of 084284.00318 30 min at rt, compound 12 (641 mg, 1.1 mmol) was added. The mixture was allowed to warm to 60 °C, and stirred for 12 h. The reaction mixture was diluted with 80 ml of EA, and washed with 20 ml. brine, then the organic phase was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified via silicon gel chromatography (0% - 20% [mixture of 3% NH40H, 22% MeOH in di chloromethane] in di chloromethane). To give 180 mg of AP53 as a pale yellow oil, yield 28.1%. 'HNMR (300 MHz, CDCh) 85.45 - 5.27 (m, 4H), 4.08 (qd, J= 6.8, 1.5 Hz, 4H), 2.77 (d, J= 11.5 Hz, 2H), 2.42 (s, 6H), 2.03 (q, J= 6.7, 5.6 Hz, 8H), 1.69 (p, J= 6.8 Hz, 4H), 1.44 - 1.20 (m, 44H), 0.90 (t, J= 6.9 Hz, 6H).31PNMR (121 MHz, CDCh) 825.07. HRMS (777 / z): [M+H]+calcd. for C39H79NO3P+ 640.5792; found: 640.5797.
[0277] AP53 was synthesized according to a similar procedure as AP52. 'H NMR (300 MHz, CDCh) 86.43 (dd, J= 3.2, 1.6 Hz, 1H), 6.25 (d, J= 3.2 Hz, 1H), 5.45 - 5.26 (m, 4H), 4.56 (s, 2H), 4.23 - 4.06 (m, 3H), 3.97 (dq, J= 10.5, 7.0 Hz, 1H), 3.85 (dt, J= 10.0, 7.1 Hz, 1H), 2.71 (dd, J= 13.0, 7.0 Hz, 1H), 2.49 (t, J= 6.8 Hz, 1H), 2.43 - 2.33 (m, 5H), 2.27 (s, 6H), 2.01 (d, J= 6.4 Hz, 8H), 1.66 (hept, J = 7.0 Hz, 4H), 1.51 (t, J= 6.6 Hz, 2H), 1.39 - 1.23 (m, 44H), 0.88 (t, J = 6.6 Hz, 3H).31P NMR (121 MHz, CDCh) 821.04.
[0278] AP54 was synthesized according to a similar procedure as AP52. 'H NMR (300 MHz, CDCh) 86.43 (dd, J = 3.2, 1.6 Hz, 1H), 6.24 (d, J= 3.2 Hz, 1H), 4.56 (s, 2H), 4.20 - 4.07107184884579.5Docket No. 084284.00363PCT of 084284.00318 (m, 3H), 4.02 - 3.91 (m, 1H), 3.91 - 3.80 (tn, 1H), 2.69 (dt, J= 13.8, 7.2 Hz, 1H), 2.46 (dt, J = 13.4, 7.1 Hz, 1H), 2.38 (s, 3H), 2.35 - 2.30 (tn, 2H), 2.24 (s, 3H), 1.74 - 1.56 (m, 4H), 1.51 (t, J = 6.6 Hz, 2H), 1.32 - 1.22 (m, 36H), 0.88 (t, J= 6.6Hz, 6H).31PNMR (121 MHz, CDCh) 821.28.
[0279] Compound 29. To a solution of 12 (2.91 g, 5.0 mmol) and DBU (1.52 g, 10.0 mmol) in 20 mL of anhydrous CHCI3 was added chloroacetone dropwise at 0 °C. The reaction mixture was warmed to 60 °C and kept stirring for 48 hours. Solvent was removed under reduced pressure and the residue was purified via silica gel chromatography. 2.71 g of compound 12 was obtained as a colorless oil, yield 84.7%.31P NMR (121 MHz, CDCh) 621.40. 'HNMR (300 MHz, CDCh) 65.67 - 5.12 (m, 4H), 4.08 (qd, J= 6.9, 2.6 Hz, 4H), 3.11 (t, J= 5.2 Hz, 1H), 2.71 (t, J = 5.1 Hz, 1H), 2.31 - 1.79 (m, 8H), 1.67 (td, J= 9.9, 5.8 Hz, 4H), 1.51 (d, J= 11.2 Hz, 3H), 1.42 -1.19 (m, 45H), 0.88 (t, J= 6.6 Hz, 6H). MS ( / «?): [M+H]+calcd. for C23H48O4P+, 419.3; found: 419.4.
[0280] AP55.rH NMR (400 MHz, Chloroform -< / ) 56.68 (s, 1H), 4.11 (dq, J = 13.6, 6.8 Hz, 4H), 2.93 (dd, J= 14.0, 6.0 Hz, 1H), 2.74 - 2.67 (m, 1H), 2.65 - 2.44 (m, 3H), 2.35 (s, 5H), 2.32- 2.00 (m, 5H), 1.76- 1.54 (m, 6H), 1.43 - 1.21 (m, 31H), 0.90 (t, J= 6.8 Hz, 6H).31PNMR (162 MHz, CDCh) 826.916.184884579.5Docket No. 084284.00363PCT of 084284.00318
[0281] AP56. 'H NMR (400 MHz, Chloroform-; / ) 54.62 (s, 1H), 4.20-4.00 (m, 4H), 3.06 - 2.86 (m, 1H), 2.85 - 2.43 (m, 4H), 2.43 - 2.21 (m, 1H), 1.72 - 1.49 (m, 8H), 1.49 - 1.16 (m, 33H), 0.88 (t, J = 6.8 Hz, 6H).31P NMR (162 MHz, Chloroform-; / ) 828.31.
[0282] AP57 To a solution of 29 (0.5 g, 3.0 mmol) in anhydrous / -BuOH (5 mL) was added amine A12 (41.2 mg, 0.22 mmol). The reaction mixture was kept stirring at 85 °C for 16 hours. Solvent was removed under reduced pressure and the residue was purified via silica gel chromatography. 56 mg of AP57 was obtained as pale-yellow oil, yield 40.0%.31P NMR (121 MHz, CDCh) 827.27. ’H NMR (400 MHz, CDCh) 8 5.46 - 5.21 (m, 4H), 4.15 - 4.01 (m, 4H), 2.90 (dd, J= 14.2, 5.9 Hz, 1H), 2.67 (dt, J= 12.8, 6.5 Hz, 1H), 2.64 - 2.36 (m, 4H), 2.32 (s, 3H), 2.26 (s, 6H), 2.00 (q, J= 6.5 Hz, 8H), 1.74 - 1.63 (m, 4H), 1.59 (p, J= 6.1 Hz, 2H), 1.40 - 1.20 (m, 47H), 0.87 (t, J = 6.9 Hz, 6H). MS m / z) [M+H]+calcd. for C29H64N2O4P+ 535.5; found: 535.6.
[0283] AP58 was synthesized according to a same procedure as AP57.31P NMR (121 MHz, CDCh) 826.70. ’H NMR (400 MHz, CDCh) 8 5.42 - 5.29 (m, 4H), 4.16 - 4.02 (m, 4H), 2.88 (dd, J= 14.1, 5.1 Hz, 1H), 2.65 (dt, J= 13.2, 7.4 Hz, 2H), 2.52 (td, J= 10.4, 4.3 Hz, 4H), 2.24 (s, 14H), 2.00 (p, J=1A Hz, 8H), 1.73 - 1.52 (m, 8H), 1.42 - 1.20 (m, 48H), 0.88 (t, J= 6.8 Hz, 6H). MS (m / z): [M+H]+calcd. for C49HIOIN304P+, 826.8; found: 826.9.109184884579.5Docket No. 084284.00363PCT of 084284.00318
[0284] AP59 was synthesized according to a same procedure as AP57.31P NMR (121 MHz, CDCI3) 827.98. ’H NMR (400 MHz, CDCI3) 8 5.45 - 5.27 (m, 8H), 4.55 - 4.27 (m, 2H), 4.08 (dq, J= 13.7, 6.7 Hz, 8H), 3.04 - 2.88 (m, 2H), 2.77 - 2.46 (m, 6H), 2.41 (s, 6H), 2.01 (q, J = 6.4 Hz, 16H), 1.74 - 1.59 (m, 10H), 1.53 - 1.17 (m, 94H), 0.88 (t, J = 6.8 Hz, 12H).
[0285] AP60 was synthesized according to a same procedure as AP57.31P NMR (121 MHz, CDCI3) 826.38. 'H NMR (400 MHz, Chloroform-c / ) 65.48 - 5.26 (m, 4H), 4.17 - 4.04 (m, 4H), 2.97 - 2.87 (m, 1H), 2.43 (d, J= 2.2 Hz, 6H), 2.38 (d, J= 16.8 Hz, 1H), 2.00 (q, J= 6.4Hz, 8H), 1.66 (qd, J = 6.9, 4.7 Hz, 4H), 1.40 (d, J = 14.8 Hz, 3H), 1.38 - 1.13 (m, 44H), 0.87 (t, J = 6.7 Hz, 6H). MS (m / z) [M+H]+calcd. for C4IHS3NO4P+, 684.6; found: 684.6.
[0286] AP61 was synthesized according to a same procedure as AP57.31P NMR (121 MHz, CDCI3) 827.75. ‘HNMR (400 MHz, CDCI3) 85.59 - 5.26 (m, 4H), 4.69 (s, 1H), 4.10 (dq, J = 13.7, 6.6 Hz, 4H), 3.04 (d, J = 13.1 Hz, 1H), 2.69 (d, J = 24.9 Hz, 4H), 2.41 (t, J = 15.6 Hz, 1H), 2.01 (q, J= 6.5 Hz, 7H), 1.66 (qd, J= 8.5, 3.8 Hz, 4H), 1.56 (s, 3H), 1.52 - 1.19 (m, 45H), 1.18 - 0.92 (m, 6H), 0.88 (t, J = 6.7 Hz, 6H). MS (m / z): [M+H]+calcd. for C43H87NO4P+, 712.6; found: 712.8.110184884579.5Docket No. 084284.00363PCT of 084284.00318
[0287] AP62 was synthesized according to a same procedure as AP57.31P NMR (121 MHz, CDCh) 5 27.45. 'H NMR (400 MHz, CDCh) 5 5.45 - 5.25 (m, 4H), 4.62 (s, 1H), 4.20 -4.00 (m, 4H), 2.95 (t, J= 12.4 Hz, 1H), 2.83 - 2.46 (m, 4H), 2.42 - 2.27 (m, 1H), 2.20 - 1.86 (m, 8H), 1.67 (td, J= 12, 4.2 Hz, 4H), 1.60 (d, J= 21.1 Hz, 4H), 1.48 - 1.08 (m, 49H), 0.88 (t, J= 6.7 Hz, 6H). MS (znz): [M+H]+calcd. for C44H87NO4P+, 724.6; found: 724.9.
[0288] Compound 36: To a solution of diethyl phosphite (2.91 g, 5.0 mmol, 1 eq.) in dry dichloromethane (5 mL) was added A, O-BSA (1.12 g, 5.5 mmol, 1.1 equiv.). The mixture was refluxed for 2-3 h, then allowed to cool to room temperature and cooled to -60 °C. A solution of the epoxide (2.06 g, 15.0 mmol, 3 equiv.) in dry di chloromethane (20 mL) was added, followed by the drop wise addition of BF3. Et2O (1.85 mL, 15.0 mmol, 3 equiv.). The reaction mixture was stirred at -60 °C for 3 h and then allowed to warm to room temperature. After overnight stirring, the mixture was evaporated under reduced pressure and the crude product was purified by column chromatography. 1.0 g of desired product was obtained as a pale yellow oil, yield 27.8%.31P NMR (121 MHz, CDCh) 828.27.XH NMR (400 MHz, CDCh) 8 5.58 - 5.18 (m, 4H), 4.24 - 4.13 (m, 1H), 4.12 - 3.98 (m, 4H), 3.52 - 3.48 (m, 2H), 2.25 - 2.09 (m, 2H), 2.09 - 1.85 (m, 8H), 1.67 (p, J= 6.7 Hz, 4H), 1.43 - 1.16 (m, 44H), 0.88 (t, J= 6.8 Hz, 6H).111184884579.5Docket No. 084284.00363PCT of 084284.00318
[0289] AP63 To a suspension of 36 (72.0 mg, 1.0 mmol) and K2CO3 (55.3 mg, 0.4 mmol) in MeCN (4 mL) was added B. The resulting mixture was warmed to 70 °C and stirred for 2 days. The mixture was filtered and concentrated, the residue was purified via silica gel chromatography.56 mg of desired product was obtained as a colorless oil, yield 82.3%.31P NMR (121 MHz, CDCI3) 828.91. ’H NMR (400 MHz, CDCh) 85.55 - 5.13 (m, 4H), 4.13 - 3.95 (m, 5H), 2.38 (dd, J= 6.7, 1.8 Hz, 2H), 2.30 (s, 6H), 2.22 - 1.82 (m, 10H), 1.66 (p, J= 6.7 Hz, 4H), 1.43 - 1.18 (m, 44H), 0.87 (t, J = 6.8 Hz, 6H).
[0290] AP64 was synthesized according to a same procedure as AP63.31P NMR (121 MHz, CDCh) 829.60. ’H NMR (300 MHz, CDCh) 8 5.66 - 5.12 (m, 4H), 4.13 - 3.94 (m, 5H), 2.83 - 2.31 (m, 7H), 2.19 - 1.81 (m, 9H), 1.66 (p, J= 6.7 Hz, 4H), 1.47 - 1.14 (m, 44H), 1.04 (t, J= 7.2 Hz, 6H), 0.87 (t, J= 6.6 Hz, 6H).
[0291] AP65 was synthesized according to the same procedure as AP63.31P NMR (121 MHz, CDCh) 8 30.99. ’H NMR (400 MHz, CDCh) 8 5.56 - 5.25 (m, 4H), 4.13 - 3.97 (m, 5H), 2.69 - 2.57 (m, 2H), 2.51 - 2.31 (m, 4H), 2.18 - 1.83 (m, 10H), 1.71 - 1.63 (m, 4H), 1.63 - 1.55 (m, 4H), 1.48 - 1.41 (m, 2H), 1.41 - 1.20 (m, 44H), 0.88 (t, J= 6.8 Hz, 6H).
[0292] AP66 was synthesized according to the same procedure as AP63.31P NMR (121 MHz, CDCh) 826.33. 'H NMR (300 MHz, CDCh) 8 5.44 - 5.27 (m, 3H), 4.16 - 3.93 (m, 5H),112184884579.5Docket No. 084284.00363PCT of 084284.00318 2.60 - 2.31 (tn, 6H), 2.30 - 2.17 (tn, 9H), 2.16 - 1.79 (m, 9H), 1.64 (h, J= 6.7 Hz, 6H), 1.43 - 1.15 (tn, 44H), 0.88 (t, J= 6.6Hz, 6H).
[0293] AP67 was synthesized according to the same procedure as AP63.31P NMR (121 MHz, CDC13) 529.95. ’H NMR (300 MHz, CDCh) 5 5.46 - 5.25 (m, 4H), 4.13 - 3.91 (m, 5H), 2.79 - 2.32 (m, 9H), 2.26 (s, 12H), 2.12 - 1.77 (m, 9H), 1.64 (q, J= 6.7 Hz, 8H), 1.38 - 1.23 (m, 44H), 0.87 (t, J= 6.6 Hz, 6H).
[0294] The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0295] The foregoing merely illustrates the principles of the disclosure. Any examples set forth in this specification are not intended to be limiting and merely set forth some of the many possible embodiments for the appended claims. Those skilled in the art will readily recognize various modifications and changes that may be made without following the example embodiments and applications illustrated and described herein, and without departing from the true spirit and scope of the following claims.
[0296] All references cited and / or discussed in this specification are incorporated herein by reference in their entirety and to the same extent as if each reference was individually incorporated by reference.113184884579.5
Claims
Docket No. 084284.00363PCT of 084284.00318 What is claimed is:
1. A lipid compound comprising a compound of Formula (I):tail unit, whereinR1 and R2 are independently Ce-30 straight or branched saturated or unsaturated alkyl chain optionally inserted with one or more ester, carbonate (-O-(C=O)-O-), amide, nitrogen (-N-) or oxygen (-O-), and R1 and R2 are optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, hydroxyl,R3 is C, N, or O,R4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, or a 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring, or R4 and R5 form a 3-6 membered homocyclic or heterocyclic ring with R3,wherein when R4 and R5 form a 3-6 membered homocyclic or heterocyclic ring with R3, the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and is optionally substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, and (-OH),114184884579.5Docket No. 084284.00363PCT of 084284.00318 wherein when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, and (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R1O)(R11)), wherein when R4 or R5 is a 3-6 membered homocyclic or heterocyclic ring, any atom on the ring is optionally substituted with one or more substituents selected from the group consisting of Ci -20 alkyl, Ci -20 alkoxyl-Ci-20 alkyl, halo-Ci -20 alkyl, hydroxy-C 1-20 alkyl, halogen, and (-OH),RIO and Rll are independently a straight or branched C1-20 alkyl chain,R6 is void, a bond, or a C1-20 straight or branched alkyl chain,wherein R6 is optionally substituted with one or more of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-C 1-20 alkyl, halogen, or (-OH),R9 is void, a bond, carbon, or nitrogen, andR7 and R8 are independently void, hydrogen, or a straight or branched C1-20 alkyl chain, or R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with R9,wherein when R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with R9, the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),wherein when R7 or R8 is a straight or branched C1-20 alkyl chain, R7 or R8 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and is optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)), andR12 and R13 are independently a straight or branched C1-20 alkyl chain115184884579.5Docket No. 084284.00363PCT of 084284.00318 wherein R12 or R13 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl.
2. The lipid compound of claim 1, wherein the head group comprises Formula (IA):(IA), whereinR6, R7, R8, and R9 are void, andR4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, or a 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring, or R4 and R5 form a 3-6 membered homocyclic or heterocyclic ring with R3,wherein when R4 and R5 form a 3-6 membered homocyclic or heterocyclic ring with R3, the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),wherein when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R1O)(R11)), andwherein when R4 or R5 is a saturated or unsaturated 3-6 membered homocyclic or heterocyclic ring, any atom on the ring may optionally be substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), andRIO and Rll are independently a straight or branched C1-20 alkyl chain.116184884579.5Docket No. 084284.00363PCT of 084284.00318 3. The lipid compound of claim 1, wherein the head group comprises Formula (IB):(IB), wherein R4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, or a 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring, wherein when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein when R4 or R5 is a 3-6 membered homocyclic or heterocyclic ring, any atom on the ring may optionally be substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),R6 is C1-20 straight or branched alkyl chain,wherein R6 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),R7 and R8 are independently void, hydrogen, or a straight or branched C1-20 alkyl chain, or R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),wherein when R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),117184884579.5Docket No. 084284.00363PCT of 084284.00318 wherein when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 are optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and R7 and R8 are optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)), andR12 and R13 are independently a straight or branched C1-20 alkyl chain,wherein R12 or R13 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl.
4. The lipid compound of claim 1, wherein the head group comprises Formula (IC):(IC), whereinR6 is C1-20 straight or branched alkyl chain,wherein R6 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),R7 and R8 are independently void, hydrogen, or a straight or branched C1-20 alkyl chain, or R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),wherein when R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),118184884579.5Docket No. 084284.00363PCT of 084284.00318 wherein when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 are optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and R7 and R8 are optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)), andR12 and R13 are independently a straight or branched C1-20 alkyl chain.
5. The lipid compound of claim 1, wherein the head group comprises Formula (ID):R4 and R5 are independently void, hydrogen, (-OH), a straight or branched C1-20 alkyl chain, or a 3-6 membered homocyclic or heterocyclic ring comprising O, N, or C in the ring,wherein when R4 or R5 is a straight or branched C1-20 alkyl chain, R4 or R5 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and is optionally terminated with (-OH), (-NH2), secondary amino (-NHR10), or tertiary amino (-N(R10)(Rll)), wherein when R4 or R5 is a 3-6 membered homocyclic or heterocyclic ring, any atom on the 3-6 membered homocyclic or heterocyclic ring may optionally be substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),RIO and Rll are independently a straight or branched C1-20 alkyl chain,R6 is a bond or a C1-20 straight or branched alkyl chain,wherein when R6 is a C1-20 straight or branched alkyl chain, R6 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),119184884579.5Docket No. 084284.00363PCT of 084284.00318 R7 and R8 are independently void, hydrogen, or a straight or branched C1-20 alkyl chain, or R7 and R8 form a 3-6 membered homocyclic or heterocyclic ring with N, wherein the 3-6 membered homocyclic or heterocyclic ring comprises O, N, or C in the ring, and may optionally be substituted at any ring position with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),wherein when R7 and R8 form 3-6 membered homocyclic or heterocyclic ring with N, each atom on the 3-6 membered homocyclic or heterocyclic ring is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH),wherein when R7 and R8 are a straight or branched C1-20 alkyl chain, R7 and R8 are optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C 1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl and R7 and R8 are optionally terminated with (-OH), primary amino (-NH2), secondary amino (-NHR12), or tertiary amino (-N(R12)(R13)),R12 and R13 are independently a straight or branched C1-20 alkyl chain,wherein R12 or R13 is optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or hydroxyl.
6. The lipid compound of claim 1, wherein R1 and R2 are independently selected from the group consisting of:-C2-20 straight or branched alkyl optionally inserted with one or more oxygen (-O-);-C2-20 alkenyl optionally substituted with C1-20 alkyl;-C2-2oalkylene-((CH2)nO)m-Ci-2o alkyl; wherein n and m are independently selected from 1-5; and -C2-ioalkylene-ester-Ci-2o linear or branched alkyl optionally substituted with C1-20 alkyl.
7. The lipid compound of any one of claims 1-6, wherein R1 and R2 are independently selected from the group consisting of:120184884579.5Docket No. 084284.00363PCT of 084284.00318121184884579.5Docket No. 084284.00363PCT of 084284.00318122184884579.5Docket No. 084284.00363PCT of 084284.00318123184884579.5Docket No. 084284.00363PCT of 084284.003188. The lipid compound of claim 1, wherein the head group is selected from the group consisting of:124184884579.5Docket No. 084284.00363PCT of 084284.003189. The lipid compound of any one of claims 1-8, wherein the compound of Formula (I) is selected from:125184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318127184884579.5Docket No. 084284.00363PCT of 084284.00318184884579.5Docket No. 084284.00363PCT of 084284.00318129184884579.5Docket No. 084284.00363PCT of 084284.00318130184884579.5Docket No. 084284.00363PCT of 084284.00318131184884579.5Docket No. 084284.00363PCT of 084284.00318132184884579.5Docket No. 084284.00363PCT of 084284.0031810. A lipid compound comprising two or more compounds of Formula (I) of claim 1:133184884579.5Docket No. 084284.00363PCT of 084284.00318wherein R9 is N,wherein k is between 0-20,wherein when k is 0, a compound of Formula (la) is bonded to a compound of Formula (Ic) by covalent bonding between R9 of the compound of Formula (la) and R9 of the compound of Formula (Ic) through a straight or branched C1-20 alkyl chain, optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-C1-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), andwherein when k is greater than 0, the compound of Formula (la) is bonded to a compound of (Ib)k by covalent bonding between R9 of the compound of Formula (la) and R9 of the compound of Formula (Ib)k through a straight or branched C1-20 alkyl chain, optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci -20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH), and the compound of (Ib)k is bonded to the compound of Formula (Ic) by covalent bonding between R9 of the compound of Formula (Ib)k and R9 of the compound of Formula (Ic) through a straight or branched C1-20 alkyl chain,134184884579.5Docket No. 084284.00363PCT of 084284.00318 optionally substituted with one or more substituents selected from the group consisting of C1-20 alkyl, C1-20 alkoxyl-Ci-20 alkyl, halo-Ci-20 alkyl, hydroxy-Ci-20 alkyl, halogen, or (-OH).
11. A lipid nanoparticle composition comprising a lipid compound of any one of claims 1-10 and a helper lipid.
12. The lipid nanoparticle composition of claim 11, wherein the helper lipid comprises a phospholipid, a structural lipid, a pegylated lipid, or a combination thereof.
13. The lipid nanoparticle composition of claim 12, wherein the phospholipid is selected from the group consisting of Dilauroyl lecithin (DLPC), Dimyristoyl phosphatidylcholine (DMPC), Dioleoyl lecithin (DOPC), Dipalmitoyl phosphatidylcholine (DPPC), Distearoyl phosphatidylcholine (DSPC), Dioleoyl phosphatidylcholine (DUPC), Palmitoyl oleoyl phosphatidylcholine (POPC), l,2-Di-O-octadecyl-sn-glycero-3-phosphocholine, l-Oleoyl-2-cholesteryldimethylsuccinoyl-sn-glycero-3-phosphocholine, 1-EIexadecyl-sn-gly cero-3 -phosphocholine, 1,2-Divinyl-sn-gly cero-3 -phosphocholine, 1,2-Diarylacyl-sn-glycero-3 -phosphocholine, l,2-Dioleoyl-sn-glycero-3-phosphorylethanolamine (DOPE), 1,2-Di-phytanoyl-sn-glycero-3-phosphoethanolamine, l,2-Distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-Diethenol-sn-glycero-3-phosphoethanolamine, 1,2-Divinyl-sn-gly cero-3 -phosphoethanolamine, l,2-Diaryl-sn-glycero-3-phosphoethanolamine, l,2-Dithiohexaenoate-sn-glycero-3-phosphoethanolamine, l,2-dioleoyl-sn-glycero-3-phosphate-(l-glycerol) sodium salt (DOPG), and combinations thereof.
14. The lipid nanoparticle composition of claim 12 or claim 13, wherein the structural lipid is selected from the group consisting of cholesterol, coprosterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof.
15. The lipid nanoparticle composition of any one of claims 12-14, wherein the pegylated-lipid is selected from the group consisting of 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (DMG-PEG), l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(poly ethylene glycol)]135184884579.5Docket No. 084284.00363PCT of 084284.00318 (DSPE-PEG), PEG-disteryl glycerol (DSG-PEG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (DAG-PEG), PEG-dipalmitoyl phosphatidylethanolamine (DPPE-PEG), or PEG-1, 2-dimyristyloxypropyl-3-amine (DMA-c-PEG), and combinations thereof.
16. The lipid nanoparticle composition of any one of claims 12-15, wherein the phospholipid is DOPE, the structural lipid is cholesterol, and the pegylated-lipid is DMG-PEG.
17. The lipid nanoparticle composition of any one of claims 12-16, further comprising an mRNA encapsulated in the lipid nanoparticle composition.
18. The lipid nanoparticle composition of claim 17, wherein the mRNA encodes a neurotrophic factor.
19. The lipid nanoparticle composition of claim 17, wherein the mRNA encodes SRY-box transcription factor 2 (Sox2), achaete-scute family bHLH transcription factor 1 (Ascl1), glial cell line-derived neurotrophic factor (GDNF), Insulin-like Growth Factor 1 (IGF-1), Ciliary Neurotrophic Factor (CNTF), Fibroblast Growth Factor 2 (FGF2), Epidermal Growth Factor (EGF), Brain-Derived Neurotrophic Factor (BDNF), or a combination thereof.
20. A method of intracellular delivery of a therapeutic agent, comprising contacting a cell or administering to a subject a lipid nanoparticle composition of any one of claims 11-19.
21. A method for treating spinal cord injury comprising administering to a subject an effective amount of a lipid nanoparticle composition of any one of claims 11-19.
22. The method of claim 21, wherein the lipid nanoparticle composition comprises a circular mRNA.
23. The method of claim 22, wherein the circular mRNA encodes SRY-box transcription factor 2 (Sox2), achaete-scute family bHLH transcription factor 1 (Ascl1), glial cell line-derived 136184884579.5Docket No. 084284.00363PCT of 084284.00318 neurotrophic factor (GDNF), Tnsulin-like Growth Factor 1 (TGF-1), Ciliary Neurotrophic Factor (CNTF), Fibroblast Growth Factor 2 (FGF2), Epidermal Growth Factor (EGF), Brain-Derived Neurotrophic Factor (BDNF), or a combination thereof.
24. The method of any one of claims 21-23, wherein the administering comprises intravenously injecting the lipid nanoparticle composition, locally delivering the lipid nanoparticle composition, or a combination thereof.
25. The method of any one of claims 21-24, wherein the spinal cord injury is selected from the group consisting of traumatic spinal cord injury, non-traumatic spinal cord injury, contusion injury, compression injury, laceration, transection, ischemic injury, inflammatory demyelination, and iatrogenic spinal cord injury, including injuries resulting from tumor resection, vascular malformations, surgical complications, or a combination thereof.137184884579.5
